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2		
ABSTRACT (346 words). 1	
Recent advances in fluorescent ligand technology have enabled the study of GPCRs in their 2	
native environment without the need for genetic modification such as addition of N-terminal 3	
fluorescent or bioluminescent tags.  Here, we have used a non-imaging plate reader 4	
(PHERAstar FS) to monitor the binding of fluorescent ligands to the human adenosine-A3 5	
receptor (A3AR; CA200645 and AV039), stably expressed in CHO-K1 cells. To verify that 6	
this method was suitable for the study of other GPCRs, assays at the human adenosine-A1 7	
receptor, and β1 and β2 adrenoceptors (β1AR and β2AR; BODIPY-TMR-CGP-12177) were 8	
also carried out.  Affinity values determined for the binding of the fluorescent ligands 9	
CA200645 and AV039 to A3AR for a range of classical adenosine receptor antagonists were 10	
consistent with A3AR pharmacology and correlated well (R2=0.94) with equivalent data 11	
obtained using a confocal imaging plate reader (ImageXpress Ultra).  The binding of 12	
BODIPY-TMR-CGP-12177 to the β1AR was potently inhibited by low concentrations of the 13	
β1-selective antagonist CGP 20712A (pKi 9.68) but not by the β2- selective antagonist ICI 14	
118551(pKi 7.40).  Furthermore, in experiments conducted in CHO K1 cells expressing the 15	
β2AR this affinity order was reversed with ICI 118551 showing the highest affinity (pKi 8.73) 16	
and CGP20712A (pKi 5.68) the lowest affinity. 17	
 18	
To determine whether the faster data acquisition of the non-imaging plate reader (~3 min per 19	
96-well plate) was suitable for high throughput screening, we screened the LOPAC library 20	
for inhibitors of the binding of CA200645 to the A3AR. From the initial 1263 compounds 21	
evaluated, 67 hits (defined as those that inhibited the total binding of 25nM CA200645 by 22	
≥40%) were identified. All compounds within the library that have medium to high affinity 23	
for the A3AR (pKi ≥6) were successfully identified.   We found three novel compounds in the 24	
library that displayed unexpected sub-micromolar affinity for the A3AR.  These were K114 25	
(pKi 6.43), retinoic acid p-hydroxyanilide (pKi 6.13) and SU 6556 (pKi 6.17).  Molecular 26	
docking of these latter three LOPAC library members provided a plausible set of binding 27	
poses within the vicinity of the established orthosteric A3AR binding pocket.  A plate reader 28	
based library screening at an untagged receptor is therefore possible using fluorescent ligand 29	
opening the possibility of its use in compound screening at natively expressed receptors. 30	
  31	
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INTRODUCTION 1	
 2	
G protein-coupled receptors (GPCRs) represent the largest family of cell surface receptors 3	
and account for approximately 4% of the entire protein-coding human genome.  There are 4	
approximately 700 separate GPCRs of which over 300 are non-olfactory receptors (Kuder et 5	
al., 2014). Based on sequence homology, five distinct families of non-olfactory receptors 6	
have been classified:  Family A/Rhodopsin, Family B/secretin, Adhesion GPCRs, Family 7	
C/Glutamate, and Family F/frizzled (Guo et al., 2012).  Family A receptors contains the 8	
largest number of the non-olfactory GPCRs and including many of the most widely studied 9	
receptors, each of which acts to translate extracellular signals into intracellular effects by 10	
activating both heterotrimeric G protein-dependent and –independent signalling cascades 11	
(Castro et al., 2005; Guo et al., 2012). Importantly, these family A GPCRs are also currently 12	
targeted by a large number of clinically used drugs and are validated targets for a significant 13	
number of drug discovery programmes. 14	
  15	
Adenosine is one biological transmitter which plays a vital homeostatic role and acts via a 16	
family of Class A GPCRs comprising four distinct subtypes: namely the adenosine-A1 17	
receptor (AR), A2AAR, A2BAR, and A3AR (Fredholm et al., 2011). Both the A1AR and 18	
A3ARs inhibit intracellular cAMP formation by activating inhibitory Gi proteins, whilst the 19	
A2AAR and A2BARs generally stimulate cAMP formation via stimulatory Gs proteins.  20	
Adenosine-mediated signalling has been implicated in a number of pathological states. For 21	
instance, the signalling pathways regulated by these receptors can promote angiogenesis 22	
(Headrick et al., 2013) and reduce inflammation (Antonioli et al., 2014). Within this family, 23	
the A3AR is a promising molecular target for the control of a range of pathological conditions 24	
including cancer (Cao et al., 2017; Joshaghani et al., 2017; Nakamura et al., 2015; Montinaro 25	
et al., 2013), inflammation (Yoshida et al., 2017; Cohen et al., 2014), autoimmune diseases 26	
(Ravani et al., 2017), ischaemia (Ohana et al., 2016; González-Fernández et al., 2014; 27	
Hussain et al., 2014; Mulloy et al., 2013) and chronic neuropathic pain (Tosh et al., 2015), 28	
making it an important target for drug development (Borea et al., 2015). As a consequence, 29	
identifying new screening methods for discovery of novel chemical scaffolds which bind to 30	
the A3AR would be beneficial. 31	
 32	
With this in mind, it is of note that recent advances in fluorescent ligand technology have 33	
enabled unlabelled GPCRs to be studied in their native environment without any need for 34	
genetic modification through the addition of a bioluminescent or fluorescent tag.  For 35	
instance fluorescent ligands have been used to study various aspects of GPCR pharmacology 36	
including ligand binding, receptor-ligand kinetics, receptor localisation and trafficking 37	
(Stoddart et al., 2015b). Of particular relevance to purinergic drug discovery, Stoddart et al. 38	
(2012) developed a competitive binding assay for the human A3AR and A1AR in live cells, 39	
using a high content screening (HCS) platform that allowed the screening of small fragment 40	
libraries. This assay system was also used to validate the pharmacology of A3AR selective 41	
compounds that were identified from virtual screening of homology models (Ranganathan et 42	
al., 2015).  However, a disadvantage of this technique is that it involves the acquisition and 43	
analysis of a large number of images which can impose severe time, data handling and 44	
storage limitations at the early stages of drug discovery, particularly in hit discovery, when 45	
very large libraries (>100,000 compounds) are used in initial screening campaigns (Tomasch 46	
et al., 2012).  In this work, we show that such a competitive fluorescent based binding screen 47	
is possible on a higher throughput, non-imaging-based platform using two structurally 48	
unrelated fluorescent antagonists. The suitability of this assay for higher throughput screens 49	
has been demonstrated by screening a library of pharmacological active compounds 50	
(LOPAC) against the native human A3AR in living cells, with a view to identifying potential 51	
novel scaffolds for A3AR ligands.  52	53	
5		
RESULTS.  1	
 2	
Comparison of high content (HCS) and high throughput (HTS) screening platforms for 3	
measuring competition binding to the A3AR. 4	
As previously described, competition binding assays have been performed on cells expressing 5	
the wild type human A3AR using the fluorescent adenosine receptor antagonist CA200645 by 6	
automated image acquisition using an ImageXpress (IX) Ultra confocal imaging plate reader 7	
(Stoddart et al., 2012).  In order to see if this method could be translated into a faster non-8	
imaging format, we directly compared HCS and plate reader based CA200645 binding by 9	
sequentially reading the same samples on the PHERAstar FS (BMG techonologies) then the 10	
IX Ultra. As shown in the IX Ultra plate image in Figure 1A, binding of 25 nM CA200645 11	
was clearly seen, and was subsequently displaced by increasing concentrations of competing 12	
(unlabelled) antagonists.  The same 96-well plate was also measured on a standard non-13	
imaging fluorescence plate reader (PHERAstar FS), with 81 separate repeat reads per well to 14	
take into account variation in cell density, and a similar pattern of fluorescence was observed 15	
(Figure 1B). The montage images from both instruments show that the high affinity A3AR 16	
antagonist MRS1220, AV019 (compound 1 in Vernall et al., (2012)) and the non-selective 17	
adenosine receptor antagonist xanthine amine congener (XAC) caused a concentration-18	
dependent reduction in the fluorescence intensity observed with 25 nM CA200645 alone.  19	
Competition binding curves were generated from the quantified data (Figure 1C), and pKi 20	
values for the five adenosine receptor antagonists obtained, which were comparable to values 21	
reported in the literature (Table 1).  Comparison of the affinity values from the HTS platform 22	
(PHERAstar) to those from the HCS platform (IX Ultra) showed a high degree of correlation 23	
(R2=0.94) (Figure 1E) and we have previously shown that affinity values obtained from the 24	
HCS platform correlated  well with values obtained in a functional assay (Stoddart et al., 25	
2012). In addition to the XAC based fluorescent ligand CA200645, a structurally distinct and 26	
highly selective fluorescent A3AR antagonist was also used in both assays (AV039; 27	
compound 19 in Vernall et al., 2012). As with CA200645, using 5 nM AV039 as label, 28	
competition binding experiments produced the expected rank order of antagonist affinity for 29	
the A3AR (Figure 1D, Table 1).  30	
 31	
Application to A1AR and β-adrenoceptors. 32	
To verify that the experimental approach used for the A3AR was suitable for the study of 33	
other GPCRs, we conducted the same experimental design with CA200645 on CHO cells 34	
expressing the human A1AR, since this fluorescent ligand also binds with high affinity to this 35	
receptor (Stoddart et al., 2012).  This is important, since being able to screen for compound 36	
selectivity is an important aspect of developing a screening methodology. As with the A3AR, 37	
a clear concentration-dependent decrease in fluorescence intensity was detected on the HTS 38	
plate reader in the presence of four different adenosine receptor antagonists (Figure 2A).  The 39	
affinity values from these data were consistent with A1AR pharmacology with CGS 15943 40	
showing the highest affinity and MRS1220 exhibiting a lower affinity than at the A3AR. In 41	
addition, ZM241385, an A2AAR selective antagonist showed the expected low affinity at the 42	
A1AR (Table 1). 43	
The confocal based fluorescent ligand binding assay has also been recently applied to study 44	
the pharmacology of the β1AR using BODIPY-TMR labelled CGP 12177 (BODIPY-TMR-45	
CGP; Gherbi et al., 2014) and we therefore also tested whether ligand binding to the β1AR 46	
and β2AR could also be monitored using the HTS platform in order to develop a counter 47	
screen for the A3AR.  As shown in Figure 2B, in CHO cells expressing either the β1AR or 48	
β2AR, binding of BODIPY-TMR-CGP could be clearly detected, and clear competition 49	
binding was observed with all three βAR ligands at both receptors. Importantly, the β1AR 50	
selective antagonist CGP 20712A displayed the highest affinity at the β1AR and the β2AR 51	
selective antagonist ICI 118551 the lowest (Table 2), whilst this rank order was reversed at 52	
6		
the β2AR, with ICI 118551 showing the highest affinity and CGP20712A the lowest affinity 1	
(Figure 2C, Table 2). 2	
 3	
Screening of a focussed library of pharmacologically active ligands at the A3AR. 4	
To determine whether the HTS version of the competitive fluorescent binding assay was 5	
suitable for the screening of large compound libraries, we chose to screen the Library of 6	
Pharmacologically Active Compounds (LOPAC) against the A3AR. The LOPAC library is 7	
considered to be a recognised standard for assay validation as it is based on an extensive 8	
number of bioactive compounds. Many of these are known to affect targets involved in 9	
adenosine receptor signalling (Iturrioz et al., 2010). CHO cells expressing the A3AR were 10	
grown to confluency in 96-well plates and incubated with a single concentration (10 µM) of 11	
the known A3AR antagonist MRS1220 as a positive control or one of the 1263 compounds 12	
(10 µM) from the LOPAC library and   CA200645 (25 nM) and the fluorescence intensity of 13	
each well determined on the PHERAstar plate reader as described in Experimental 14	
Procedures. Hits were defined as those compounds which inhibited the binding of CA200645 15	
by >40%, and of the initial 1263 compounds evaluated, 67 hits were identified (Supporting 16	
Information Table 1; Figure 3). Inhibition data for all the compounds tested in the initial 17	
screen can be found in Supporting Information Table 1. Among the hits, all the compounds 18	
within the library with medium to high affinity for the A3AR (pKi ≥6; Figure 3; Table 3) were 19	
identified along with four low affinity adenosine-related molecules (1,3-dipropyl-8-p-20	
sulfophenylxanthine, DMPX, etazolate hydrochloride and 2-phenylaminoadenosine; Table 3). 21	
This confirmed the utility of this approach to identify compounds with known A3AR binding 22	
affinity. Importantly, the assay Z’ factor was 0.47 ± 0.03 (mean ± SEM, n = 97), 23	
demonstrating its suitability for screening larger libraries in living cells. 24	
 25	
 Ten hits from the initial screen which demonstrated the biggest inhibition of CA200645 26	
binding to the A3AR were investigated further and full inhibition curves for each compound 27	
were generated.  We were unable to further test reactive blue 2 (position 4 in the full screen) 28	
as it is currently not available commercially. As shown in Table 4 and Figure 4, four of the 29	
top ten compounds showed low- to sub-micromolar affinity for the A3AR. As expected the 30	
adenosine receptor antagonist CGS15943 displaced the binding of CA200645 at both the 31	
A3AR and A1AR in a concentration-dependent manner with the expected affinity (Table 1, 32	
Figure 4).  As CGS15943 was one of the top ten hits from the initial screen it was also tested 33	
in cells expressing the β2AR and had no effect on the binding of BODIPY-TMR-CGP (Figure 34	
4).  Three further compounds, retinoic acid p-hydroxyanilide (fenretinide), K114 and SU 35	
6656, were found to inhibit the binding of CA20065 to the A3AR in a concentration-36	
dependent manner with affinity values in the sub-micromolar range, roughly 10-fold lower 37	
than CGS15943  (Figure 4 and Table 4).  Five further hits (BIO, rottlerin, quercetin, 38	
PD173952 and kenpaullone) only displaced the binding of CA200645 at the highest 39	
concentration tested (10 µM), prohibiting an accurate affinity determination.  For those four 40	
compounds showing micromolar affinity, the selectivity of their interaction with the A3AR 41	
was determined by investigating their ability to bind to A1AR and β2AR. Both K114 and 42	
retinoic acid p-hydroxyanilide inhibited the binding of CA200645 at the A1AR with similar 43	
affinity to that observed at the A3AR.  SU 6656 only inhibited binding at the highest 44	
concentration tested and the affinity was not calculated.  None of the other compounds 45	
showed any measureable activity at the A1AR.  When tested in CHO cells expressing β2AR, 46	
no significant inhibition of BODIPY-TMR-CGP binding was observed for any of the ten 47	
compounds screened but the control β2AR antagonist propranolol had the expected affinity 48	
(pKi = 8.72 ± 0.14, n = 3) .  There was an increase in fluorescence in the presence of 10 µM 49	
SU 6656 (128.4 ± 18.4%).  However this was small compared to the increase seen with 10 50	
nM BODIPY-TMR-CGP and the large increase in fluorescence in the presence of BIO 51	
(pEC50 = 5.84 ± 0.13).  This is likely to be due to these compounds interfering with the 52	
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BODIPY-TMR fluorescence signal, which was not observed when using the more red-shifted 1	
BODIPY 630/650 fluorophore in the A1AR and A3AR binding assays. 2	
  3	
 4	
Molecular modelling of selected LOPAC hits at the A3AR. 5	
Using our previously established homology model of the human A3AR (Vernall et al., 2013) 6	
we sought to investigate potential binding poses for the three sub-micromolar compounds 7	
(retinoic acid p-hydroxyanilide (fenretinide), K114 and SU 6656) identified in the LOPAC 8	
screen which did not have previous literature precedent for interacting with this receptor sub-9	
type.  Using the commercially available docking software, CLC Drug Discovery Workbench, 10	
ligand and receptor binding pocket preparation was followed by targeted ligand docking.  The 11	
highest scoring docked poses for K114, SU 6656 and retinoic acid p-hydroxyanilide were 12	
selected and are illustrated in Fig 5.  All three compounds were able to engage via plausible 13	
poses to the A3R within the vicinity of the orthosteric binding pocket of this receptor. 14	 	15	16	
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DISCUSSION 1	
Fluorescent ligands for GPCRs are a valuable tool in the study of multiple aspects of receptor 2	
pharmacology and they are a potential replacement for radiolabelled ligands in saturation and 3	
equilibrium binding studies to determine the affinity of labelled and unlabelled ligands 4	
(Stoddart et al., 2016).  In this study, we aimed to further develop a previously described 5	
fluorescence based live cell binding assay that used a high content screening (HCS) system 6	
(Stoddart et al., 2012) to an assay that could be performed with un-tagged receptors on a high 7	
throughput screening (HTS) system.  To this end, we chose the PHERAstar FS fluorescent 8	
plate reader since it allowed the determination of the optimal focal height for the fluorescence 9	
read and multiple scans per well. Use of the HTS system to obtain data resulted in a marked 10	
reduction in the time each 96-well plate took to process; from around 40 minutes per plate on 11	
the confocal HCS system for data collection and analysis to less than 3 minutes for the HTS 12	
system.  This also produced a significant reduction in the amount of data that needed to be 13	
stored; 500 Mb per plate for HCS versus 160 Kb for HTS.  Using the A3AR as a model 14	
system, we demonstrated that the data generated on the HTS system was in close agreement 15	
to that obtained on the HCS system, validating this system as a higher throughput 16	
methodology that would be essential for screening large compound libraries using 17	
fluorescence-based binding assays in whole cells.   18	
Various methods using fluorescent ligands to measure ligand binding at GPCRs have been 19	
recently developed, each using a different approaches to measure the fluorescence of the 20	
bound ligand, including flow cytometry (Hara et al., 2009; Kozma et al., 2013; Young et al., 21	
2005), fluorescence polarization (Cornelius et al., 2009; Kecskes et al., 2010) and resonance 22	
energy transfer based systems (Stoddart et al., 2015a; Zwier et al., 2010). Each method has 23	
advantages and disadvantages, for instance ligand depletion (fluorescence polarization) and 24	
the need to tag the receptor of interest (BRET and FRET).  One limitation of the simple 25	
fluorescent intensity measurement used in the system described here is the potential for a low 26	
signal/noise ratio as a result of high levels of non-specific binding and the use of whole cells. 27	
As this technique measures total well fluorescence intensity it will be affected by both high 28	
levels of non-specific membrane binding and also non-specific uptake of the fluorescent 29	
ligand into the cells. As an example of this, for the A3AR the maximal reduction in the levels 30	
of CA200645 fluorescence measured in the presence of unlabelled ligands was 60% whilst 31	
that with BODIPY-TMR-CGP for the β1AR was only 20% (Figure 1C and 2B).  This small 32	
signal/noise ratio for this ligand at the β1AR has been observed previously (Gherbi et al., 33	
2014), although it is notable that even under these conditions, the method described here still 34	
allowed us to generate robust data within this small signal/noise window.  The proximity-35	
based assays (e.g. NanoBRET; Stoddart et al., 2015) overcome this issue but they obviously 36	
require genetic modification of the extracellular N-terminus of the receptor with a fluorescent 37	
or luminescent protein, which precludes their use on native receptors – a main aim of the 38	
assay developed in this study. What is also clear from this point of view, is that the limit of 39	
this signal to noise ratio is likely to be highly dependent on both the pharmacological and 40	
photophysical properties of the fluorescent ligand, as we have previously demonstrated 41	
(Vernall et al., 2013). To progress the use of this assay to use with endogenously expressed 42	
untagged receptors, consideration should also be given to fluorescent ligand selectivity in 43	
situations where multiple receptor subtypes are often co-expressed; this is particularly true for 44	
adenosine receptors. To this end, the demonstration that this assay also works with a highly 45	
A3AR selective ligand, AV039 (Vernall et al., 2012) is important. 46	
To demonstrate the utility of this assay system for compound screening, we investigated if we 47	
could identify known ligands for the A3AR within a library of pharmacologically active 48	
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compounds (LOPAC).  Within the LOPAC library there were 37 compounds identified as 1	
ligands for adenosine receptors.  For the 1263 compounds screened, we defined a hit as a 2	
compound that inhibited more than 40% of the total CA200645 binding.  Using these criteria, 3	
we identified 67 hits, of which 14 had previously described activity at adenosine receptors 4	
(Table 3).  Of these, four were the known A3R selective agonists, 2-Cl-IB-MECA (Gallo-5	
Rodriguez et al., 1994), IB-MECA (Klotz et al., 1998), AB-MECA (Klotz et al., 1998) and 6	
HEMADO (Klotz et al., 2007), and the A3R selective antagonist MRS1523 (Li et al., 1998).  7	
A further five compounds were known to be non-selective at this adenosine receptor subtype 8	
(CGS15943 (Ongini et al., 1999), NECA (Gao et al., 2004), APNEA (Gao et al., 2004), 2-9	
CADO (van Galen et al., 1994) and 1,3-dipropyl-8-p-sulfophenylxanthine (Daly et al., 10	
1985)).  The remaining four compounds were SCH 58261, CV1808, DPCPX and FSCPX.  11	
SCH 58261 is widely described as an A2A selective and DPCPX as an A1AR-selective 12	
antagonist, and both retain affinity in the µM range for the A3AR (Jacobson et al., 2006; 13	
Stoddart et al., 2012).  FSCPX is an irreversible antagonist at the A1AR (van Muijlwijk-14	
Koezen et al., 2001) but to date it had not been tested at other adenosine receptor subtypes. 15	
Our data from this screen indicates that FSCPX is likely to retain activity at the A3R at least 16	
in the low µM range and this is also true for CV1808 that has been described as an agonist at 17	
the A2AAR (Dionisotti et al., 1997).  A variety of different compounds that act at different 18	
(i.e. non-A3AR) adenosine receptors were included in the library and as expected were not 19	
identified as hits in our screen (Supplementary Table 1). These included A1AR selective 20	
agonists and antagonists such as R-PIA (Klotz et al., 1998) and CPT (Dalpiaz et al., 1998), 21	
A2AAR selective agonists and antagonists such as CGS 21680 (Klotz et al., 1998) and CSC 22	
(Jacobson et al., 1993), and the A2BAR selective antagonist alloxazine (Ji et al., 2001).  A 23	
variety of low affinity non-selective antagonists and agonists were also present in the library 24	
including adenosine, theophylline, caffeine and paraxanthine that have reported affinity at the 25	
A3AR in the 13-100 µM range (Fredholm et al., 2001; Jacobson et al., 1999).  Due to the 26	
concentration of CA200645 (25nM) used in the primary screen only compounds with an 27	
affinity of <10µM would be expected to be identified as a hit.  Overall, the assay performed 28	
well at identifying all the compounds with known activity at the A3AR. 29	
We found three compounds in the library that displayed unexpected sub-micromolar affinity 30	
at the A3AR (Figure 4 and Table 4).  These were K114, retinoic acid p-hydroxyanilide and 31	
SU 6556.  K114 is used to identify amyloid lesions from Aβ peptide, α-synuclien and tau 32	
through an increase in its fluorescence upon binding to these lesions.  It is has minimal 33	
fluorescence in aqueous solution and has emission maxima of 550 nm that is unlikely to 34	
interfere with the emission of BY630 at 650 nm (Crystal et al., 2003). In addition, the assay 35	
described here monitors a decrease in fluorescence in the presence of inhibitors that would 36	
mean it would be more likely to give false-negatives rather than false-positives.  Retinoic 37	
acid p-hydroxyanilide, also known as fenretinide or 4-HPR, is an analogue of retinoic acid 38	
and is a potential therapy in the treatment of cancer due to its ability to induce apoptosis (Wu 39	
et al., 2001).  It is possible that it was causing apoptosis of the cells in our assay system 40	
leading to a concurrent decrease in fluorescence but as the presence of retinoic acid p-41	
hydroxyanilide had no effect in cells expressing the β2AR this is unlikely to be the case 42	
(Figure 4).  SU6556 is a Src kinase inhibitor that has also been found to inhibit a variety of 43	
other kinases including Aurora C and AMPK (Bain et al., 2007).  It also displayed slight 44	
selectivity for the A3AR over A1AR.  45	
Docking of the sub-micromolar compounds identified in the LOPAC screen provided a 46	
plausible set of binding poses within the vicinity of the established orthosteric A3AR binding 47	
pocket (Figure 5).  K114 bound in a fully extended form with one of the terminal phenols 48	
optimally positioned to engage in a hydrogen bond interaction with the side-chain of Thr94.  49	
Meanwhile, the remaining vinyl-linked aromatic moieties pass through a hydrophobic 50	
10		
channel created by Ile76, Val169, Leu90, Leu246, Ile249, Leu264, Ile268 and Phe168; the 1	
latter engaging via a face-to-face pi-stacking interaction. SU 6656 favoured binding higher up 2	
in the orthosteric pocket with the 4,5,6,7-tetrahydroindolyl portion of the molecule engaging 3	
in a face-to-face interaction with Phe168, with the hydrophobic interactions predominating 4	
with Leu90, Val65, Ile268 and Leu246.  Finally, retinoic acid p-hydroxyanilide displayed a 5	
binding pose passing through the same hydrophobic channel observed with K114.  The 1,3,3-6	
trimethylcyclohex-1-enyl region of the molecule was positioned deepest into the binding 7	
pocket engaging in hydrophobic interactions with residues Leu246, Ile249, Met177 and 8	
Phe168.  The p-hydroxyanilde region of the molecule was positioned in such a way as to 9	
allow a face-to-edge interaction with Tyr265 at the top of transmembrane helix 7.  With the 10	
predominance of aromatic and hydrophobic interactions observed between the receptor and 11	
the three ligands discussed, this would seem to correlate well with the experimental binding 12	
affinities whilst also offering the potential to undertake productive modifications of these 13	
compounds to potentially enhance their overall binding interactions. 14	
 In conclusion, we have shown that a simple intensity based fluorescent ligand binding assay 15	
can be modified to work in a potentially high throughput format, giving significant advances 16	
in both speed and data volume compared to previous high content versions. The assay allows 17	
screening of a small compound library in live cells, and can assess binding to the unmodified 18	
native receptors. The assays performed well under test conditions, identifying both known 19	
adenosine receptor ligands in a focussed library as well as novel potential ligand scaffolds. 20	
Further work on establishing this assay to screen at endogenous A3AR in a mixed receptor 21	
background will be important to allow subsequent screens to be performed under more 22	
physiological conditions. 23	24	
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EXPERIMENTAL PROCEDURES 1	
Chemicals 2	
Known GPCR antagonists were purchased from Tocris Bioscience and G418 was obtained 3	
from Invitrogen. Fetal calf serum was obtained from PAA Laboratories and L-glutamine 4	
from Lonza. All other biological reagents were obtained from Sigma-Aldrich. CA200645 was 5	
obtained from CellAura Technologies. BODIPY-TMR-CGP (BODIPY-TMR-(±)-CGP 6	
12177) was purchased from Molecular Probes. AV039 was synthesized in house as 7	
previously described (Vernall et al., 2012). The LOPAC library was obtained from Sigma-8	
Aldrich. 9	
 10	
Cell Culture 11	
CHO-K1 cells stably expressing the human A3AR (Vernall et al., 2012), β1AR (Guo et al., 12	
2012), β2AR (Baker et al., 2002) or the human A1AR (May et al., 2010) were maintained in 13	
DMEM/F12 medium containing 10% foetal calf serum and 2 mM L-glutamine at 37°C in a 14	
humidified atmosphere of air/CO2 (19:1). 15	
 16	
Fluorescence Competition Binding Assay 17	
CHO cells stably expressing the A3AR, A1AR, β1AR or β2AR were seeded into the central 60 18	
wells (for high content confocal analysis) or every well (high throughput analysis) of a 96-19	
well clear-bottomed, black-walled plate (Greiner BioOne) and grown to confluency. On the 20	
day of experiment, normal growth medium was removed and cells washed twice with 21	
HEPES-buffered saline solution (HBSS; 25 mM HEPES, 10 mM glucose, 145 mM NaCl, 5 22	
mM KCl, 1 mM MgSO4, 2 mM sodium pyruvate, 1.3 mM CaCl2, pH 7.4) pre-warmed to 23	
37°C. Fresh HBSS was added to each well followed by the addition of the required 24	
concentration of unlabelled compound and the respective fluorescent ligands (25 nM 25	
CA200645, 5 nM AV039 or 10 nM BODIPY-TMR-CGP). Cells were incubated for 1h at 26	
37°C/5% CO2. Buffer was then removed from each well, cells washed once in HBSS and 27	
fresh HBSS added at room temperature. Plates were then immediately subjected to high 28	
content or high throughput screening analysis as detailed below.   29	
High content screening 30	
High content analysis was conducted as previously described (Stoddart et al., 2012). Briefly, 31	
plates were imaged using an ImageXpress Ultra confocal plate reader, which captured four 32	
central images per well using a Plan Fluor 40x NA0.6 extra-long working distance objective. 33	
CA200645 was excited at 635 nm and emission collected through a 640-685 nm band pass 34	
filter. Total image intensity was obtained using a modified multi-wavelength cell scoring 35	
algorithm within the MetaXpress software (MetaXpress 2.0, Molecular Devices).  36	
High throughput screening 37	
High throughput analysis was performed using a PHERAstar FS plate reader (BMG 38	
Technlogies). Fluorescent intensity of each well was assessed by bottom scanning using the 39	
following optical modules: excitation 540 nm and emission 590 nm (for BODIPY-TMR-40	
CGP-labelled cells), or excitation 630 nm and emission 650 nm (for the BY630 compounds 41	
CA200645 and AV039). Optimal focal height was determined automatically and total 42	
fluorescence intensity was assessed by taking 81 reads per well.  43	
 44	
Screening of the LOPAC library of pharmacological active compounds 45	
The LOPAC compound library contained 1263 compounds and each compound was provided 46	
as a pre-dissolved solution in 10 mM in DMSO. Compound plates containing 2 µl of 47	
compound per well were provided by the University of Nottingham Managed Compound 48	
Collection.  Each plate contained 40 compounds from the LOPAC library together with 49	
positive and blank control samples.  For the blank controls, 2 µl of DMSO was added per 50	
well and for the positive controls the A3AR antagonist MRS1220 (10µM final concentration) 51	
12		
was used. The compounds were diluted to 100 µM in HBSS prior to assay.  Each compound 1	
was tested in duplicate at a final concentration of 10µM on three separate experimental days.   2	
Experiment was carried out as detailed above using the A3AR expressing cell line and 25 nM 3	
CA200645 as the tracer ligand. Data were normalised on a per plate basis to the fluorescence 4	
observed in blank control wells.  5	
The 67 compounds that inhibited by more than 40% the total binding of CA200645 compared 6	
to blank controls were classed as hits.  From this list 16 compounds were selected for 7	
secondary screening to determine their IC50 values and binding affinity.  This was achieved 8	
by investigating the effect of increasing concentrations of each inhibitor on the specific 9	
binding of 25 nM CA200645 or 10 nM BODIPY-TMR-CGP in cells expressing the A3AR, 10	
A1AR or β2AR.  11	
Molecular Modelling 12	
Using our previously reported homology model of the human A3AR (Vernall et al., 2013) 13	
and the CLC Drug Discovery Workbench software package (Version 3.0.2, Qiagen, 14	
Netherlands), the protein target was prepared with no water molecules present.  Before 15	
setting up the docking experiments, the binding site was generated as a 13 Å sphere centred 16	
around the established orthosteric pocket. All small molecules were constructed using 17	
ChemDraw Professional 16.0 (CambridgeSoft, Cambridge, MA, USA) and imported into the 18	
docking programme using the Balloon PlugIn (http://users.abo.fi/mivainio/balloon) (Vainio et 19	
al., 2007) to afford the lowest energy conformer for each ligand.  During the docking process, 20	
each ligand underwent 1000 individual iterations, with the conformation of each ligand set as 21	
flexible, allowing full movement around all rotatable bonds, whilst the protein was held as a 22	
rigid structure.  The best scoring pose for each ligand was returned using the PLANTSPLP 23	
algorithm to determine that docking score (Korb et al., 2009) and the best ranked compounds 24	
were selected and their binding residues observed using the CLC Drug Discovery Workbench 25	
visualization tool. 26	
 27	
Data analysis 28	
 Competition binding curves were fitted to the following equation using GraphPad Prism 5 29	
(GraphPad Software): 30	 % !"ℎ!"!#!$% !" !"#$%&%$ !"#$"#% = 100×[!]! + !"!" 
 31	
where [A] is the concentration of competing drug and IC50 is the molar concentration of 32	
ligand required to inhibit 50% of the specific binding of a fixed concentration [L] of the 33	
appropriate fluorescent ligand.  The IC50 values obtained were converted to Ki values using 34	
the following equation: 35	
 36	 !! =  !"!"1+  [!]!!  
where [L] is the concentration and KD is the equilibrium dissociation constant of the 37	
fluorescent ligand  .  The KD values for the fluorescent ligands used were 11.0 nM and 3.11 38	
nM for CA200645 at the A1AR and A3AR respectively (Stoddart et al., 2012). KD values for 39	
BODIPY-TMR-CGP were taken from Baker et al., (2003).   40	
 41	
The Z’ values were calculated on a per plate basis using the following equation: 42	
 43	 !! = 1−  3(!! +  !!)!! −  !!  
 44	
13		
where µp and σp are the mean and standard deviation from the control wells (DMSO only) 1	
and µn and σn are the mean and standard deviation from the MRS1220 treated wells. 2	
  3	
 4	
5	
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FIGURE LEGENDS 1	
Figure 1.  Competition binding at the A3AR using fluorescent ligands.  CHO cells 2	
expressing the A3AR were incubated with 25 nM CA200645 and increasing concentrations of 3	
MRS1220, XAC or AV019.  (A) Four images per well were obtained on the ImageXpress 4	
confocal plate reader and resulting images shown as a montage.  (B) Montage fluorescence 5	
intensity measurement of the same plate obtained using the BMG PheraStar FS where blue, 6	
green, yellow and red pixels represents increasing intensity of fluorescence. (C) Competition 7	
curves at the A3AR generated from the total fluorescence intensity measured on the 8	
PHERAstar FS microplate reader for five adenosine receptor antagonists. (D) CHO A3AR 9	
cells were incubated with increasing concentrations of antagonist and 5 nM AV039 for 1h, 10	
37oC, washed and fluorescence intensity assessed using the PHERAstar FS. (E) Correlation 11	
between pKi values obtained using the IX Ultra (high content screening; HCS) and the 12	
PHERAstar FS (high throughput screening; HTS) for the data obtained using CA200645 as 13	
fluorescent ligand. Data were normalized to the maximal intensity observed per experiment 14	
and each data point represents the mean ± SEM from n number of experiments (See Table 1) 15	
performed in triplicate.  16	
 17	
Figure 2. Competition binding assays at the adenosine A1 and β1/β2-adrenoceptors. 18	
CHO cell lines stably expressing A1AR (A), β1AR (B) or the β2AR (C) were incubated with 19	
25 nM CA200645 (A1AR) or 10 nM BODIPY-TMR-CGP (β1AR and β2AR), in the absence 20	
or the presence of increasing concentrations of antagonists. Fluorescence intensity in each 21	
well was monitored using the PHERAstar FS. Values are mean ± SEM from 3 - 6 22	
independent experiments performed in triplicate. 23	
 24	
Figure 3. Screening the LOPAC library against the A3AR.  Example of the data generated 25	
from one plate of compounds from the LOPAC library.  Each plate contained 40 compounds 26	
(each at 10µM final concentration) from the LOPAC library in duplicate along with four 27	
basal and four MRS1220 (10 µM) controls, also in duplicate. The fluorescence intensities 28	
obtained on the PHERAstar FS from this plate are shown as mean and range of duplicates 29	
with the hits highlighted in red and adenosine indicated in blue.  The plate shown is a 30	
representative plate of one of the three experiments performed using these compounds and 31	
the inhibition data for all compounds screened can be found in Supporting Table 1.  32	
 33	
Figure 4. Competition binding curves at the A1AR, A3AR and β2AR for three hits 34	
identified from the LOPAC library. CHO cell lines stably expressing A1AR (A), A3AR (B) 35	
or β2AR (C) were incubated with 25 nM CA200645 (A3AR and A1AR) or 10 nM BODIPY-36	
TMR-CGP  (β2AR) in the absence or in the presence of increasing concentrations of the 37	
indicated compounds. Values are mean ± SEM from three independent experiments 38	
performed in triplicate. 39	
 40	
Figure 5. Molecular modelling simulation of K114, SU 6656 and retinoic acid p-41	
hydroxyanilide binding to the A3AR. A side-on (A, C and E) and top-down (B, D and F) 42	
view of the top scoring binding poses for K114, SU 6656 and retinoic acid p-hydroxyanilide 43	
(dark grey liquorice colouring) respectively, bound into our previously reported A3AR 44	
receptor homology model (Vernall et al., 2013). Previously identified amino acid side chain 45	
residues associated with the orthosteric binding pocket (Squarcialupi et al., 2013) are 46	
represented in light grey liquorice colouring and labelled alongside the TM loop regions for 47	
clarity. 48	
15		
 1	2	
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TABLES 1	
Table 1. Affinity of compounds measured at the A1AR and A3AR: Affinity values from 2	
the PHERAstar HTS assay for unlabelled ligands measured on CHO cells expressing the 3	
A3AR or the A1AR using 25 nM  CA200645 or 5 nM AV039.  Values represent mean ± SEM 4	
from n number of experiments performed in triplicate. ND = not determined. Literature 5	
values for both A3AR and A1AR taken from Stoddart et al., 2012.  6	
 7	
 8	
 9	
 10	
 11	
 12	
 13	
 14	
 15	
  16	
 A3AR  A1AR  
 CA200645 AV039  CA200645  
 pKi n pKi n Literature 
Values 
pKi n Literature 
Values 
MRS1220 9.30 ± 0.32 5 9.21 ± 
0.12 
6 9.02  7.35 ± 
0.19 
5 7.14 
AV019 8.82 ± 0.28 4 ND - 8.51 ND - 5.93 
XAC 8.06 ± 0.16 5 8.04 ± 
0.22 
4 7.85 7.70 ± 
0.08 
4 7.54 
CGS1594
3 
7.91 ± 0.20 3 7.91 ± 
0.01 
3 8.18 8.35 ± 
0.16 
3 8.95 
ZM24138
5 
6.63 ± 0.20 3 6.32 ± 
0.28 
3 6.74 6.54 ± 
0.04 
3 6.68 
17		
Table 2. Affinity of compounds measured at the β1AR and β2AR: Affinity values for β-1	
adrenoceptor ligands measured in CHO cells expressing the β1AR or the β2AR using 10 nM 2	
of BODIPY-TMR-CGP in the HTS format fluorescent ligand binding assay.  Values 3	
represent mean ± SEM from three experiments performed in triplicate.  4	
 5	
 β1AR β2AR 
 pKi n pKi N 
Propranolol 8.89 ± 0.16 3 9.00 ± 0.09 3 
CGP 20712A 9.68 ± 0.12 3 5.68 ± 0.06 3 
ICI 118,551 7.40 ± 0.03 3 8.73 ± 0.07 3 
 6	
 7	
 8	
 9	
  10	
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Table 3. Known A3AR ligands in the LOPAC library: Compounds  within the LOPAC library that have known activity at adenosine receptors, their 1	
rank order in the full screen and the % of 25 nM CA200645 binding in the presence of 10 µM of these compounds 2	
 3	
Name 
Agonist or 
Antagonist 
LOPAC description 
& Total 
CA200645 
binding 
Rank 
CGS 15943 Antagonist Potent non-selective adenosine receptor antagonist 30.0 ± 3.0  9 
2-Cl-IB-MECA Agonist A3 adenosine receptor agonist 32.3 ± 6.1 12 
IB-MECA Agonist Selective A3 adenosine receptor agonist 36.3 ± 4.0 18 
NECA Agonist Adenosine receptor agonist 38.1 ± 4.3 20 
HEMADO Agonist A3 adenosine receptor agonist 40.1 ± 10.5 24 
APNEA Agonist Non-selective adenosine receptor agonist 41.0 ± 7.2 26 
1,3-dipropyl-8-p-
sulfophenylxanthine Antagonist Adenosine receptor antagonist (slight selectivity for A1 over A2) 42.3 ± 4.8 29 
AB-MECA Agonist High affinity A3 adenosine receptor agonist 49.5 ± 5.8 38 
2-CADO Agonist Adenosine receptor agonist with selectivity for A1 over A2 51.0 ± 6.7 43 
SCH 58261 Antagonist A2A adenosine receptor antagonist 52.2 ± 5.4 47 
CV1808 Agonist Selective A2 adenosine receptor agonist 53.3 ± 19.9 56 
DPCPX Antagonist Selective A1 adenosine receptor antagonist 56.3 ± 3.4 58 
FSCPX Antagonist Irreversible A1 adenosine receptor antagonist 57.5 ± 23.0 63 
MRS 1523 Antagonist Selective A3 adenosine receptor antagonist in rat 58.3 ± 11.4 64 
 4	
19		
Table 4. Affinity of selected hits from the LOPAC library at the A3AR, A1AR and β2AR: Compounds were tested on CHO cells expressing the 1	
A3AR, A1AR and β2AR in the HTS format fluorescent ligand binding assay using 25 nM CA200645 as the tracer for A3AR and A1AR and 10 nM of 2	
BODIPY-TMR-CGP for β2AR.  Data represents mean ± SEM from three experiments performed in triplicate.  ND = not determined as accurate curve 3	
could not be generated.  4	
 5	
  A3AR A1AR β2AR 
Position in 
primary screen 
Compound  pKi  pKi  % Total binding at 
10 µM 
2 SU 6656 6.17 ± 0.08 ND 128.4 ± 18.4 
5 K114 6.43 ± 0.04 6.56 ± 0.11 95.8 ± 5.5  
8 Retinoic acid p-
hydroxyanilide 
6.13 ± 0.18 6.04 ± 0.21 102.7 ± 5.1 
9 CGS 15943 7.24 ± 0.14 8.14 ± 0.09 115.4 ± 5.0 
 6	
 7	
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Table 1. Inhibition of CA200645 binding at the A3AR by the LOPAC library of compounds. 
Values obtained in a fluorescent adenosine receptor antagonist binding assay using whole, live cells 
expressing the A3AR.  Values quoted are % of control wells (wells containing 1% DMSO and 25 nM 
CA200645). All compounds were tested at 10 µM.  Data shown represents mean ± SD from three 
separate experiments performed in duplicate.  ND = not determined as compounds were not included 
in the screen.  
Rank Compound Name % 25 nM 
CA200645 
binding 
 Rank Compound Name % 25 nM 
CA200645 
binding 
1 BIO 16.1 ± 3.2  641 1-(4-Chlorobenzyl)-5-methoxy-2-
methylindole-3-acetic acid 
97.1 ± 10.6 
2 SU 6656 17.3 ± 1.8  642 Etodolac 97.1 ± 13.7 
3 Rottlerin 22.8 ± 1.4  643 Anisotropine methyl bromide 97.1 ± 12.3 
4 Reactive Blue 2 24.5 ± 2.7  644 Metrazoline oxalate 97.1 ± 2.0 
5 K114 24.6 ± 5.8  645 Ebastine 97.2 ± 6.4 
6 Quercetin dihydrate 25.2 ± 6.9  646 (+)-Brompheniramine maleate 97.2 ± 7.4 
7 PD173952 25.6 ± 5.3  647 Citalopram hydrobromide 97.2 ± 4.4 
8 Retinoic acid p-hydroxyanilide 26.5 ± 2.0  648 1,5-Isoquinolinediol 97.2 ± 4.1 
9 CGS-15943 30.0 ± 3.0  649 Paroxetine hydrochloride 
hemihydrate 
97.2 ± 4.3 
10 Kenpaullone 30.6 ± 6.6  650 S(-)-Atenolol 97.2 ± 11.6 
11 DAPH 31.8 ± 9.9  651 (±)-CPP 97.2 ± 1.5 
12 Chloro-IB-MECA 32.3 ± 6.1  652 Captopril 97.2 ± 6.3 
13 PD-166866 34.3 ± 9.7  653 U0126 97.2 ± 19.0 
14 Rutaecarpine 34.3 ± 2.1  654 8-(p-Sulfophenyl)theophylline 97.2 ± 13.7 
15 PD 169316 35.7 ± 3.3  655 Nisoxetine hydrochloride 97.3 ± 6.5 
16 1,3,5-tris(4-hydroxyphenyl)-4-
propyl-1H-pyrazole 
35.7 ± 9.6  656 Imiloxan hydrochloride 97.3 ± 10.2 
17 AGK2 35.8 ± 5.6  657 CHM-1 hydrate 97.3 ± 5.3 
18 IB-MECA 36.3 ± 4.0  658 IMID-4F hydrochloride 97.3 ± 5.7 
19 U-74389G maleate 36.9 ± 10.8  659 SKF-89145 hydrobromide 97.3 ± 9.6 
20 5'-N-Ethylcarboxamidoadenosine 38.1 ± 4.3  660 (±)-Methoxyverapamil 
hydrochloride 
97.3 ± 10.6 
21 CL 316,243 38.7 ± 18.1  661 Venlafaxine hydrochloride 97.3 ± 8.5 
22 Calcimycin 38.9 ± 3.3  662 CGS-12066A maleate 97.3 ± 10.3 
23 Sanguinarine chloride 38.9 ± 20.6  663 Vinpocetine 97.3 ± 11.5 
24 HEMADO 40.1 ± 10.4  664 Sunitinib malate 97.4 ± 12.4 
25 SP600125 41.0 ± 10.4  665 Imazodan 97.4 ± 12.7 
26 N6-2-(4-
Aminophenyl)ethyladenosine 
41.0 ± 7.1  666 Atropine sulfate 97.4 ± 1.9 
27 6(5H)-Phenanthridinone 41.6 ± 14.1  667 DL-Cycloserine 97.4 ± 8.2 
28 Apigenin 41.8 ± 13.4 
 
 668 (±)-Vanillylmandelic acid 97.4 ± 12.9 
29 1,3-Dipropyl-8-p-
sulfophenylxanthine 
42.3 ± 4.8  669 Sepiapterin 97.4 ± 20.7 
30 SU 5416 43.3 ± 10.8 
 
 670 Albuterol hemisulfate 97.4 ± 12.0 
31 DL-Stearoylcarnitine chloride 44.2 ± 6.0  671 4-Aminobenzamidine 
dihydrochloride 
97.4 ± 8.5 
32 Roscovitine 45.3 ± 8.6  672 Diltiazem hydrochloride 97.4 ± 8.9 
33 AS-252424 45.8 ± 20.9  673 CGP-13501 97.4 ± 7.1 
34 Etazolate hydrochloride 46.2 ± 5.3  674 L-741,626 97.5 ± 15.5 
35 Eupatorin 47.2 ± 12.7  675 Sematilide monohydrochloride 
monohydrate 
97.5 ± 2.4 
36 Imperatorin 47.6 ± 2.3  676 Tomoxetine 97.5 ± 8.3 
37 AB-MECA 48.5 ± 9.1  677 1-Allyl-3,7-dimethyl-8-p-
sulfophenylxanthine 
97.5 ± 9.3 
38 Furafylline 49.5± 5.8  678 Gabaculine hydrochloride 97.5 ± 8.4 
39 SB 242084 dihydrochloride 
hydrate 
49.6± 12.4  679 Eprosartan mesylate 97.5 ± 15.0 
40 MNS 50.1 ± 14.8  680 Labetalol hydrochloride 97.5 ± 13.9 
41 Indirubin-3'-oxime 50.6 ± 24.7  681 Cantharidic Acid 97.5 ± 13.0 
42 PD-184161 50.8 ± 14.3  682 SCH-28080 97.5 ± 14.8 
43 2-Chloroadenosine 51.0 ± 6.7  683 Bendamustine hydrochloride 97.6 ± 4.1 
44 SB 218795 51.1 ± 8.4  684 Chlorpropamide 97.6 ± 7.8 
45 Diacylglycerol Kinase Inhibitor II 51.5 ± 9.4  685 Oxaprozin 97.6 ± 6.3 
46 (±)-2-Amino-7-
phosphonoheptanoic acid 
52.2 ± 10.8  686 Agmatine sulfate 97.6 ± 11.6 
47 UCL 2077 52.2 ± 5.4  687 PMEG hydrate 97.6 ± 14.8 
48 SCH 58261 52.5 ± 9.7  688 gamma-Acetylinic GABA 97.6 ± 3.0 
49 Emodin 52.8± 4.4  689 Carboplatin 97.7 ± 5.9 
50 SU 4312 53.2 ± 16.7  690 DBO-83 97.7 ± 11.0 
51 N-Oleoyldopamine 53.5 ± 8.3  691 L(-)-Norepinephrine bitartrate 97.7 ± 6.2 
52 NU2058 53.9 ± 7.1  692 loxoprofen 97.7. ± 0.7 
53 Gossypol 54.1 ± 12.3  693 Podophyllotoxin 97.7 ± 17.3 
54 Calmidazolium chloride 54.4 ± 19.1  694 5-Hydroxy-L-tryptophan 97.7 ± 1.5 
55 PF-573228 54.7 ± 30.2  695 Atorvastatin calcium salt 
trihydrate 
97.7 ± 2.2 
56 2-Phenylaminoadenosine 55.3 ± 19.9  696 Moclobemide 97.8 ± 6.0 
57 GW7647 55.8 ± 12.2  697 Piribedil maleate 97.8 ± 1.7 
58 8-Cyclopentyl-1,3-
dipropylxanthine 
56.3 ± 3.4  698 (-)-Naproxen sodium 97.8 ± 4.0 
59 Nifedipine 56.6 ± 11.1  699 5-Aminovaleric acid 
hydrochloride 
97.9 ± 5.1 
60 FSCPX 57.1 ± 9.1  700 SKF 83959 hydrobromide 97.9 ± 6.2 
61 MRS 1523 57.3 ± 10.9  701 N-Bromoacetamide 97.9 ± 5.0 
62 GW2974 57.3 ± 11.9  702 BIX 01294 trihydrochloride 
hydrate 
97.9 ± 21.2 
63 Tyrphostin AG 879 57.5 ± 23.0  703 Oxiracetam 97.9 ± 12.4 
64 AS 604850 58.3 ± 11.4  704 S(-)-Pindolol 98.0 ± 8.4 
65 7-Cyclopentyl-5-(4-
phenoxy)phenyl-7H-pyrrolo[2,3-
d]pyrimidin-4-ylamine 
58.8 ± 13.2  705 Amisulpride 98.0 ± 5.3 
66 1-benzoyl-5-methoxy-2-
methylindole-3-acetic acid 
59.0 ± 9.2  706 L-Cycloserine 98.0 ± 1.4 
67 AMG 9810 59.0 ± 6.4  707 (±)-7-Hydroxy-DPAT 
hydrobromide 
98.0 ± 1.6 
68 (+)-Bromocriptine 
methanesulfonate 
60.6 ± 9.2  708 3-Isobutyl-1-methylxanthine 98.0 ± 7.1 
69 SB 206553 hydrochloride 60.7 ± 9.3  709 SB-215505 98.1 ± 14.8 
70 N6-Methyladenosine 61.1 ± 11.7  710 Fluphenazine dihydrochloride 98.1 ± 12.0 
71 IRAK-1/4 Inhibitor I 61.3 ± 9.4  711 Demeclocycline hydrochloride 98.1 ± 10.5 
72 TNP 61.8 ± 11.7  712 L-Buthionine-sulfoximine 98.1 ± 5.3 
73 Myricetin 62.7 ± 9.0  713 cis(+/-)-8-OH-PBZI 
hydrobromide 
98.1 ± 5.1 
74 IPA-3 63.1 ± 15.2  714 Cytosine-1-beta-D-
arabinofuranoside hydrochloride 
98.1 ± 3.7 
75 LY-367,265 64.8 ± 25.8  715 EBPC 98.2 ± 13.5 
76 O6-benzylguanine 65.0 ± 6.0  716 Quinacrine dihydrochloride 98.2 ± 4.9 
77 Thapsigargin 65.1 ± 10.7  717 Vinblastine sulfate salt 98.2 ± 16.0 
78 YC-1 65.3 ± 4.7  718 N-Oleoylethanolamine 98.2 ± 10.8 
79 Mecamylamine hydrochloride 65.4 ± 10.0  719 Guanabenz acetate 98.2 ± 11.7 
80 CGS-21680 hydrochloride 65.7 ± 8.4  720 Tetrahydrozoline hydrochloride 98.2 ± 6.4 
81 Genistein 66.1 ± 12.2  721 BRL 37344 sodium 98.2 ± 9.4 
82 Psora-4 66.4 ± 9.2  722 CP-346086 dihydrate 98.2 ± 12.5 
83 Mephetyl tetrazole 66.4 ± 18.5  723 (±)-8-Hydroxy-DPAT 
hydrobromide 
98.2 ± 1.8 
84 G15 66.5 ± 16.0  724 Tyrphostin AG 537 98.3 ± 17.8 
85 Fusaric acid 66.5 ± 29.0  725 BU99006 98.3 ± 5.1 
86 Cilnidipine 67.0 ± 19.0  726 Actinonin 98.3 ± 4.3 
87 WIN 62,577 67.3 ± 5.6  727 HA-100 98.3 ± 9.4 
88 (-)-Bicuculline methbromide, 
1(S), 9(R) 
67.4 ± 5.9  728 Ammonium 
pyrrolidinedithiocarbamate 
98.3 ± 7.2 
89 TBB 67.4 ± 13.4  729 Famotidine 98.3 ± 15.4 
90 Phloretin 67.7 ± 15.2  730 Pancuronium bromide 98.3 ± 10.5 
91 7,8-Dihydroxyflavone hydrate 68.2 ± 13.0  731 1,10-Diaminodecane 98.3 ± 12.0 
92 CCT007093 68.4 ± 3.4  732 Sodium Taurocholate hydrate 98.3 ± 7.3 
93 SB 202190 68.5 ± 12.1  733 Bestatin hydrochloride 98.3 ± 9.7 
94 S(-)-p-Bromotetramisole oxalate 68.6 ± 44.8  734 Clodronic acid 98.4 ± 3.5 
95 CyPPA 68.8 ± 15.9  735 Betaxolol hydrochloride 98.4 ± 4.9 
96 Cisplatin 69.0 ± 8.2  736 N-Desmethylclozapine 98.4 ± 14.7 
97 R(-)-N6-(2-
Phenylisopropyl)adenosine 
69.2 ± 26.4  737 D-ribofuranosylbenzimidazole 98.4 ± 15.0 
98 N6-Cyclopentyladenosine 69.6 ± 6.1  738 ATPO 98.4 ± 3.3 
99 AA-861 69.6 ± 8.4  739 RepSox 98.5 ± 5.4 
100 6-Hydroxy-DL-DOPA 69.7 ± 9.9  740 Parthenolide 98.5 ± 15.3 
101 KRM-III 70.4 ± 12.2  741 SIB 1757 98.5 ± 4.5 
102 R(-)-Apocodeine hydrochloride 70.5 ± 34.0  742 DL-erythro-Dihydrosphingosine 98.5 ± 11.2 
103 I-OMe-Tyrphostin AG 538 71.3 ± 34.4  743 Thiolactomycin 98.5 ± 7.2 
104 1-(1-Naphthyl)piperazine 
hydrochloride 
71.5 10.7  744 p-Fluoro-L-phenylalanine 98.5 ± 8.4 
105 PD-156707 71.9 ± 8.4  745 LE 300 98.5 ± 4.5 
106 Morin 72.1 ± 9.6  746 1-Deoxynojirimycin 
hydrochloride 
98.5 ± 11.6 
107 Ro 90-7501 72.1 ± 6.0  747 Disopyramide phosphate 98.5 ± 7.6 
108 (±)-Chloro-APB hydrobromide 72.6 ± 20.5  748 (-)-Scopolamine,n-Butyl-, 
bromide 
98.5 ± 15.4 
109 Celecoxib 72.6 ± 20.4  749 CP-100263 dihydrochloride 
hydrate 
98.5 ± 6.9 
110 Indomethacin 72.9 ± 18.3  750 L-allylglycine 98.5 ± 1.7 
111 U-73122 73.1 ± 7.4  751 Nomifensine maleate 98.5 ± 14.7 
112 Tyrphostin AG 835 73.1 ± 6.8  752 Succinylcholine chloride 98.6 ± 15.7 
113 Chelerythrine chloride 73.9 ± 3.7  753 EGTA 95.6 ± 5.9 
114 Clotrimazole 74.0 ± 15.0  754 4-Imidazoleacrylic acid 95.6 ± 8.4 
115 FPL 64176 74.2 ± 6.7  755 Cetirizine dihydrochloride 98.6 ± 19.3 
116 TBBz 74.5 ± 15.0  756 (+)-Butaclamol hydrochloride 98.6 ± 1.9 
117 AL-8810 75.0 ± 17.3  757 (-)-Isoproterenol hydrochloride 98.6 ± 14.4 
118 Flupirtine maleate 75.3 ± 9.1  758 Y-27632 dihydrochloride 98.6 ± 10.3 
119 Dephostatin 75.4 ± 19.6  759 Zonisamide sodium 98.6 ± 10.8 
120 Cilostamide 75.9 ± 3.4  760 L-3,4-Dihydroxyphenylalanine 
methyl ester hydrochloride 
98.6 ± 13.3 
121 10058-F4 75.9 ± 8.5  761 Naftopidil dihydrochloride 98.6 ± 14.2 
122 WB-4101 hydrochloride 76.0 ± 5.8  762 (±)-threo-1-Phenyl-2-
decanoylamino-3-morpholino-1-
propanol hydrochloride 
98.6 ± 11.0 
123 SB-525334 76.3 ± 9.5  763 S(+)-Raclopride L-tartrate 98.6 ± 4.9 
124 alpha-Guanidinoglutaric acid 76.4 ± 9.5  764 Rolipram 98.7 ± 10.9 
125 Olvanil 76.7 ± 2.8  765 Tropicamide 98.7 ± 3.0 
126 SB 222200 76.8 ± 5.5  766 Histamine, R(-)-alpha-methyl-, 
dihydrochloride 
98.7 ± 8.4 
127 FAUC 213 76.8 ± 3.4  767 5alpha-Pregnan-3alpha-ol-11,20-
dione 
98.7 ± 9.4 
128 Betamethasone 77.0 ± 7.6  768 Felbamate 98.7 ± 4.1 
129 L-798106 77.1 ± 10.4  769 Nilutamide 98.7 ± 10.0 
130 p-Iodoclonidine hydrochloride 77.2 ± 42.2  770 4-Hydroxyphenethylamine 
hydrochloride 
98.7 ± 19.0 
131 CP-154526 hydrochloride 77.3 ± 23.1  771 N-(3,3-
Diphenylpropyl)glycinamide 
98.7 ± 7.8 
132 Nelfinavir mesylate hydrate 77.3 ± 17.3  772 MK-886 98.7 ± 12.2 
133 TG003 77.3 ± 17.0  773 Semicarbazide hydrochloride 98.7 ± 22.6 
134 6-Fluoronorepinephrine 
hydrochloride 
77.6 ± 28.4  774 Ciprofibrate 98.7 ± 5.2 
135 CP-64434 hydrate 77.6 ± 21.9  775 CP-471474 98.7 ± 17.5 
136 Hispidin 77.8 ± 19.6  776 Eliprodil 98.8 ± 8.5 
137 R(+)-6-Bromo-APB 
hydrobromide 
77.8 ± 20.1  777 5-Fluorouracil 98.8 ± 8.7 
138 7-Chloro-4-hydroxy-2-phenyl-
1,8-naphthyridine 
77.8 ± 8.8  778 Ro 41-0960 98.8 ± 6.8 
139 GR 79236X 78.0 ± 19.3  779 Benazoline oxalate 98.8 ± 14.3 
140 Ellipticine 78.2 ± 23.8  780 Tryptamine hydrochloride 98.8 ± 5.7 
141 GYKI 52466 hydrochloride 78.2 ± 10.4  781 Dicyclomine hydrochloride 98.9 ± 10.8 
142 Pimozide 78.2 ± 10.9  782 Supercinnamaldehyde 98.9 ± 0.6 
143 Gallamine triethiodide 78.3 ± 38.7  783 Tracazolate 98.9 ± 4.3 
144 BF-170 hydrochloride 78.6 ± 20.5  784 Azithromycin dihydrate 98.9 ± 6.9 
145 Betaine hydrochloride 78.7 ± 15.6  785 Phentolamine mesylate 98.9 ± 10.7 
146 Dipyridamole 78.8 ± 14.8  786 Tiapride hydrochloride 98.9 ± 15.2 
147 Disopyramide 78.9 ± 27.0  787 4-
Amidinophenylmethanesulfonyl 
fluoride hydrochloride 
98.9 ± 8.1 
148 PNU-282987 78.9 ± 33.0  788 Oleic Acid 98.9 ± 11.8 
149 Nocodazole 79.0 ± 5.7  789 Bupropion hydrochloride 98.9 ± 4.9 
150 Piceatannol 79.1 ± 22.1  790 Phosphomycin disodium 98.9 ± 12.7 
151 L-165,041 79.1 ± 19.7  791 Benserazide hydrochloride 98.9 ± 5.3 
152 Felodipine 79.1 ± 13.7  792 Ketoconazole 98.9 ± 9.0 
153 Cyclophosphamide monohydrate 79.2 ± 18.9  793 2-Methylthioadenosine 
triphosphate tetrasodium 
99.0 ± 0.7 
154 Cefaclor 79.3 ± 20.7  794 Triflupromazine hydrochloride 99.0 ± 16.0 
155 Caffeic acid phenethyl ester 79.3 ± 10.7  795 N-Acetyltryptamine 99.0 ± 14.1 
156 Nordihydroguaiaretic acid from 
Larrea divaricata (creosote bush) 
79.3 ± 28.3  796 Benzamide 99.1 ± 4.7 
157 Ritanserin 79.4 ± 12.5  797 Moxonidine hydrochloride 99.1 ± 3.2 
158 8-(3-Chlorostyryl)caffeine 79.6 ± 7.9  798 L-3,4-Dihydroxyphenylalanine 99.1 ± 9.5 
159 Loxapine succinate 80.2 ± 12.7  799 Theophylline 99.1 ± 10.8 
160 Phorbol 12-myristate 13-acetate 80.3 ± 5.6  800 3-(1H-Imidazol-4-yl)propyl di(p-
fluorophenyl)methyl ether 
hydrochloride 
99.1 ± 1.1 
161 NU6027 80.6 ± 9.9  801 Altretamine 99.1 ± 9.2 
162 ET-18-OCH3 80.6 ± 4.5  802 8-Methoxymethyl-3-isobutyl-1-
methylxanthine 
99.2 ± 10.1 
163 Promazine hydrochloride 80.6 ± 8.4  803 Formoterol 99.2 ± 6.5 
164 erythro-9-(2-Hydroxy-3-
nonyl)adenine hydrochloride 
80.7 ± 17.0  804 Aminoguanidine hemisulfate 99.2 ± 8.4 
165 PD 98,059 80.7 ± 2.6  805 Diethylenetriaminepentaacetic 
acid 
99.2 ± 10.9 
166 Gabapentin 80.7 ± 22.8  806 Imipramine hydrochloride 99.2 ± 4.6 
167 Debrisoquin sulfate 81.0 ± 16.3  807 (±)-Chlorpheniramine maleate 99.2 ± 9.9 
168 Phenserine 81.1 ± 29.6  808 PF-4708671 99.2 ± 13.5 
169 3-Bromo-7-nitroindazole 81.2 ± 6.7  809 Dihydroergotamine 
methanesulfonate 
99.2 ± 11.1 
170 CGP 57380 81.2 ± 23.0  810 (±)-6-Chloro-PB hydrobromide 99.3 ± 4.1 
171 Fenspiride hydrochloride 81.2 ± 5.0  811 Hydroxylamine hydrochloride 99.3 ± 3.4 
172 cDPCP 81.3 ± 5.4  812 Guvacine hydrochloride 99.3 ± 14.1 
173 Clofibrate 81.3 ± 24.9  813 (-)-Quinpirole hydrochloride 99.3 ± 13.8 
174 Esomeprazole magnesium 
dihydrate 
81.5 ± 16.8  814 2,3-Dimethoxy-1,4-
naphthoquinone 
99.3 ± 8.8 
175 Tyrphostin 1 81.6 ± 2.9  815 (-)-Physostigmine 99.3 ± 6.1 
176 SB 200646 hydrochloride 81.7 ± 19.9  816 Imidazole-4-acetic acid 
hydrochloride 
99.3 ± 14.9 
177 Arecoline hydrobromide 81.8 ± 27.0  817 L-Aspartic acid 99.3 ± 3.7 
178 N-Succinyl-L-proline 81.8 ± 11.2  818 CP-335963 99.3 ± 11.5 
179 Staurosporine aglycone 81.9 ± 6.1  819 Mexiletene hydrochloride 99.4 ± 6.9 
180 Pentoxifylline 81.9 ± 17.4  820 Ritodrine hydrochloride 99.4 ± 8.5 
181 AMN082 81.8781336
7 
 821 (±)-cis-Piperidine-2,3-
dicarboxylic acid 
99.4 ± 1.9 
182 Fenoterol hydrobromide 81.9 ± 17.1  822 Trihexyphenidyl hydrochloride 99.4 ± 5.7 
183 Fenobam 81.9 ± 15.0  823 Artemether 99.4 ± 9.9 
184 Auranofin 82.1 ± 31.0  824 (±)-SKF-38393 hydrochloride 99.4 ± 9.0 
185 SANT-1 82.1 ± 15.9  825 Hexamethonium bromide 99.4 ± 1.1 
186 2',3'-didehydro-3'-
deoxythymidine 
82.1 ± 11.9  826 Phenelzine sulfate 99.4 ± 7.6 
187 Ro 04-6790 dihydrochloride 82.1 ± 15.5  827 N-Methylhistaprodifen dioxalate 
salt 
99.4 ± 7.3 
188 3'-Azido-3'-deoxythymidine 82.3 ± 18.1  828 S-(+)-PD 123177 trifluoroacetate 
salt hydrate 
99.4 ± 7.4 
189 S-(p-Azidophenacyl)glutathione 82.4 ± 8.6  829 AIDA 99.4 ± 5.4 
190 Wortmannin from Penicillium 
funiculosum 
82.6 ± 17.7  830 Clomipramine hydrochloride 99.4 ± 3.8 
191 BRL 50481 82.8 ± 17.4  831 Lorglumide sodium 99.4 ± 5.5 
192 BMY 7378 dihydrochloride 82.8 ± 23.0  832 (+)-Norfenfluramine 
hydrochloride 
99.5 ± 11.3 
193 Pergolide methanesulfonate 82.8 ± 15.4  833 S-Nitrosoglutathione 99.5 ± 12.8 
194 Ibudilast 82.8 ± 12.0  834 8-Bromo-cAMP sodium 99.5 ± 9.1 
195 Palmitoyl-DL-Carnitine chloride 82.9 ± 21.8  835 Flumazenil 99.5 ± 3.5 
196 Lercanidipine hydrochloride 
hemihydrate 
82.9 ± 16.7  836 NCS-382 99.5 ± 31.9 
197 R(-)-2,10,11-
Trihydroxyaporphine 
hybrobromide 
83.0 ± 14.1  837 O-
(Carboxymethyl)hydroxylamine 
hemihydrochloride 
99.5 ± 10.8 
198 MRS 2159 83.0 ± 11.6  838 Domperidone 99.6 ± 10.5 
199 R-(+)-8-Hydroxy-DPAT 
hydrobromide 
83.0 ± 17.5  839 DL-Homatropine hydrobromide 99.6 ± 8.1 
200 Tamoxifen 83.1 ± 23.3  840 (±)-Baclofen 99.6 ± 6.9 
201 (±)-Octoclothepin maleate 83.2 ± 25.2  841 Sandoz 58-035 99.6 ± 12.7 
202 L-701,324 83.2 ± 4.8 
 
 842 (S)-(+)-Camptothecin 99.7 ± 12.1 
203 Clozapine 83.2 ± 22.9  843 TPMPA 99.7 ± 3.7 
204 SC-57461A 83.2 ± 13.1  844 Clemizole hydrochloride 99.7 ± 8.2 
205 (±)-Metoprolol (+)-tartrate 83.3 ± 9.2  845 (±)-SKF 38393, N-allyl-, 
hydrobromide 
99.7 ± 11.6 
206 AS605240 83.4 ± 13.4  846 (±)-alpha-Lipoic Acid 99.7 ± 5.6 
207 SCH-202676 hydrobromide 83.4 ± 13.1  847 Trandolapril 99.7 ± 12.5 
208 CPNQ 83.4 ± 4.6  848 Trimethoprim 99.7 ± 13.3 
209 1-Aminobenzotriazole 83.5 ± 18.8  849 (-)-Scopolamine hydrobromide 99.7 ± 17.0 
210 Kynurenic acid 83.5 ± 10.7  850 Thioperamide maleate 99.7 ± 10.4 
211 Urapidil, 5-Methyl- 83.5 ± 22.8  851 1-Methylhistamine 
dihydrochloride 
99.7 ± 10.5 
212 Mifepristone 83.5 ± 5.2  852 Allopurinol 99.8 ± 7.2 
213 CP-226269 83.6 ± 17.8  853 Corticosterone 99.8 ± 5.3 
214 Ganaxolone 83.6 ± 13.4  854 N-Ethylmaleimide 99.8 ± 13.3 
215 Amitriptyline hydrochloride 83.6 ± 19.8  855 (-)-cis-(1S,2R)-U-50488 tartrate 99.8 ± 10.5 
216 AC-55649 83.6 ± 13.2  856 Valproic acid sodium 99.8 ± 9.6 
217 trans-(±)-ACPD 83.6 ± 13.4  857 Doxazosin mesylate 99.9 ± 9.5 
218 L-Cysteinesulfinic Acid 83.6 ± 21.3  858 Amsacrine hydrochloride 99.8 ± 8.3 
219 BAY 61-3606 hydrochloride 
hydrate 
83.8 ± 10.8  859 (±)-2-Amino-4-phosphonobutyric 
acid 
99.9 ± 8.9 
220 Reserpine 83.8 ± 14.9  860 Imetit dihydrobromide 99.9 ± 2.2 
221 NF 023 83.8 ± 25.8  861 Tulobuterol hydrochloride 99.9 ± 4.7 
222 K 185 84.1 ± 1.4  862 U-73343 99.9 ± 5.3 
223 Hydrocortisone 84.4 ± 24.1  863 Acyclovir 99.9 ±13.7 
224 Flutamide 84.4 ± 23.0  864 BTO-1 99.9 ± 23.7 
225 Sulindac sulfone 84.5 ± 13.2  865 L-Glutamine 99.9 ± 14.1 
226 Pyrilamine maleate 84.6 ± 34.1  866 Lithium Chloride 99.9 ± 5.2 
227 JX401 84.6 ± 8.9  867 Diclofenac sodium 100.0 ± 12.4 
228 Cefmetazole sodium 84.6 ± 22.3  868 DL-Thiorphan 100.0 ± 12.5 
229 Pindolol 84.7 ± 11.8  869 Quipazine, 6-nitro-, maleate 100.0 ± 4.7 
230 Ziprasidone hydrochloride 
monohydrate 
84.7 ± 3.4  870 Choline bromide 100.0 ± 6.6 
231 Chlormethiazole hydrochloride 84.7 ± 21.7  871 L-Tryptophan 100.0 ± 3.7 
232 N-Methyl-beta-carboline-3-
carboxamide 
84.9 ± 8.4  872 3,5-Dinitrocatechol 100.0 ± 11.8 
233 4-DAMP methiodide 84.9 ± 19.8  873 SKF 96365 100.0 ± 16.7 
234 Tyrphostin 23 84.9 ± 6.4  874 AFMK 100.0 ± 2.7 
235 Loratadine 85.0 ± 1.8  875 Caffeic Acid 100.0 ± 4.2 
236 SB 415286 85.0 ± 3.4  876 R(-)-Me5 100.1 ± 8.0 
237 DNQX 85.0 ± 6.8  877 Leflunomide 100.1 ± 5.3 
238 Spiperone hydrochloride 85.1 ± 18.3  878 Methotrexate hydrate 100.1 ± 8.9 
239 5alpha-Pregnan-3alpha-ol-20-one 85.2 ± 19.4  879 Tranylcypromine hydrochloride 100.1 ± 11.2 
240 13-cis-retinoic acid 85.2 ± 2.9  880 Ketanserin tartrate 100.1 ± 15.2 
241 Cyclobenzaprine hydrochloride 85.3 ± 24.5  881 Avridine 100.2 ± 21.9 
242 5'-Amino-5'-deoxyadenosine p-
toluenesulfonate salt 
85.5 ± 26.7  882 Neostigmine bromide 100.2 ± 23.4 
243 5-Carboxamidotryptamine 
maleate 
85.7 ± 14.5  883 NS 2028 100.2 ± 8.6 
244 Tetracaine hydrochloride 85.8 ± 26.7  884 (S)-Propranolol hydrochloride 100.2 ± 8.9 
245 p-Benzoquinone 85.9 ± 13.7  885 9-Amino-1,2,3,4-
tetrahydroacridine hydrochloride 
100.2 ± 15.6 
246 (R,R)-cis-Diethyl tetrahydro-2,8-
chrysenediol 
85.9 ± 6.0  886 D-Serine 100.2 ± 11.0 
247 Dequalinium chloride hydrate 86.1 ± 10.0  887 THIP hydrochloride 100.3 ± 3.4 
248 Etoposide 86.3647168
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 888 PRE-084 100.3 ± 14.3 
249 SMER28 86.4 ± 8.7  889 Lansoprazole 100.3 ± 13.0 
250 N-Acetylprocainamide 
hydrochloride 
86.4 ± 17.7  890 Resveratrol 100.3 ± 16.3 
251 Danazol 86.4 ± 9.1  891 Ketoprofen 100.3 ± 5.0 
252 Papaverine hydrochloride 86.6 ± 22.0  892 7,7-Dimethyl-(5Z,8Z)-
eicosadienoic acid 
100.3 ± 12.4 
253 Dihydrocapsaicin 86.7 ± 9.6  893 2-(Methylthio)adenosine 5'-
diphosphate trisodium salt 
hydrate 
100.3 ± 5.3 
254 (±)-3-(3,4-dihydroxyphenyl)-2-
methyl-DL-alanine 
86.8 ± 7.1  894 N-Acetyl-L-Cysteine 100.3 ± 0.2 
255 Biperiden hydrochloride 86.9 ± 6.4  895 Pentamidine isethionate 100.3 ± 6.3 
256 Cephalosporin C zinc salt 86.9 ± 28.2  896 Fulvestrant 100.4 ± 12.1 
257 SC-51322 86.9 ± 5.7  897 (-)-alpha-Methylnorepinephrine 100.4 ± 6.1 
258 SDZ-205,557 hydrochloride 87.0 ± 9.3  898 PPNDS tetrasodium 100.4 ± 12.5 
259 Me-3,4-dephostatin 87.0 ± 11.0  899 L-Histidine hydrochloride 100.4 ± 6.4 
260 CBIQ 87.1 ± 7.0  900 (±)-2,3-Dichloro-alpha-
methylbenzylamine 
hydrochloride 
100.4 ± 9.9 
261 (±)-Norepinephrine (+)bitartrate 87.1 ± 8.1  901 6,7-ADTN hydrobromide 100.4 ± 8.1 
262 1-(4-Hydroxybenzyl)imidazole-2-
thiol 
87.3 ± 21.6  902 Phenamil methanesulfonate 100.4 ± 3.8 
263 A-77636 hydrochloride 87.3 ± 8.5  903 Granisetron hydrochloride 100.4 ± 14.5 
264 Isoguvacine hydrochloride 87.4 ± 16.5  904 N-Acetyl-5-hydroxytryptamine 100.5 ± 7.6 
265 Brefeldin A from Penicillium 
brefeldianum 
87.5 ± 5.2  905 Opipramol dihydrochloride 100.5 ± 7.4 
266 5-(N,N-hexamethylene)amiloride 87.5 ± 4.4  906 (-)-Epinephrine bitartrate 100.5 ± 6.3 
267 CP-91149 87.6 ± 14.6  907 Linezolid 100.5 ± 2.1 
268 Fenofibrate 87.6 ± 17.1  908 Praziquantel 100.5 ± 15.0 
269 CGP-7930 87.6 ± 4.9  909 Ceftriaxone sodium 100.5 ± 11.9 
270 XCT790 87.7 ± 9.0  910 Hydralazine hydrochloride 100.6 ± 8.6 
271 beta-Estradiol 87.8 ± 13.4  911 (±)-AMT hydrochloride 100.6 ± 12.5 
272 1-(2-Chlorophenyl)-1-(4-
chlorophenyl)-2,2-dichloroethane 
87.8 ± 23.1  912 L-655,708 100.6 ± 12.8 
273 DCEBIO 87.8 ± 8.9  913 Uridine 5'-diphosphate sodium 100.6 ± 5.7 
274 Isoliquiritigenin 88.0 ± 9.1  914 Yohimbine hydrochloride 100.6 ± 0.5 
275 CP-380736 88.0 ± 4.4  915 Hydroquinone 100.7 ± 6.6 
276 SB 204741 88.1 ± 14.4 
 
 916 E-64 100.7 ± 6.0 
277 Sildenafil citrate salt 88.1 ± 8.0  917 Olprinone hydrochloride 100.7 ± 4.5 
278 Edrophonium chloride 88.1 ± 20.0  918 L-azetidine-2-carboxylic acid 100.7 ± 4.1 
279 Tetraethylthiuram disulfide 88.1 ± 9.2  919 N-Methyl-1-deoxynojirimycin 100.7 ± 20.9 
280 Doxycycline hydrochloride 88. 2 ± 13.0  920 Hexamethonium dichloride 100.8 ± 9.2 
281 Trequinsin hydrochloride 88.3 ± 40.0  921 BU224 hydrochloride 100.8 ± 7.2 
282 1-Aminocyclopropanecarboxylic 
acid hydrochloride 
88.3 ± 14.5  922 Z-L-Phe chloromethyl ketone 100.8 ± 7.1 
283 CPCCOEt 88.3 ± 3.9  923 Carvedilol 100.8 ± 14.2 
284 Ethosuximide 88.4 ± 5.5  924 Iofetamine hydrochloride 100.8 ± 7.1 
285 R(+)-3PPP hydrochloride 88.4 ± 12.1  925 Vancomycin hydrochloride from 
Streptomyces orientalis 
100.8 ± 8.6 
286 Tyrphostin AG 698 88.4 ± 5.8  926 Cefsulodin sodium salt hydrate 100.8 ± 6.6 
287 SIB 1893 88.4 ± 9.6  927 1,7-Dimethylxanthine 100.9 ± 19.4 
288 Icilin 88.5 ± 5.8  928 Forskolin 100.9 ± 7.2 
289 N,N-Dihexyl-2-(4-
fluorophenyl)indole-3-acetamide 
88.5 ± 10.2  929 BW 284c51 100.9 ± 3.8 
290 Isonipecotic acid 88.5 ± 19.5  930 Rilmenidine hemifumarate 100.9 ± 6.4 
291 Amiloride hydrochloride 88.5 ± 23.0  931 5,7-Dichlorokynurenic acid 100.9 ± 8.8 
292 Mitoxantrone 88.5 ± 12.7  932 Rufinamide 100.9 ± 12.8 
293 (-)-Scopolamine methyl bromide 88.5 ± 14.0  933 Aminoguanidine hydrochloride 100.9 ± 6.1 
294 Pirenperone 88.6 ± 5.4  934 GR 46611 100.9 ± 13.0 
295 Dofetilide 88.8 ± 14.7  935 Pregnenolone sulfate sodium 100.9 ± 23.1 
296 Perphenazine 88.8 ± 23.6  936 Fluvoxamine maleate 100.9 ± 16.7 
297 Nefiracetam 88.8 ± 23.8  937 3-n-Propylxanthine 101.0 ± 10.1 
298 IC 261 88.8 ± 5.2  938 R-(-)-Desmethyldeprenyl 
hydrochloride 
101.0 ± 11.7 
299 Daidzein 88.9 ± 6.0  939 Cephalexin hydrate 101.0 ± 8.0 
300 Pyrazinecarboxamide 88.9 ± 26.1  940 Propionylpromazine 
hydrochloride 
101.0 ± 0.8 
301 p-Aminoclonidine hydrochloride 89.0 ± 23.3  941 RX 821002 hydrochloride 101.0 ± 17.5 
302 R(-)-2,10,11-Trihydroxy-N-
propylnoraporphine 
hydrobromide 
89.0 ± 14.4  942 Piroxicam 101.0 ± 12.2 
303 (S)-MAP4 hydrochloride 89.0 ± 15.4  943 Oxybutynin Chloride 101.0 ± 12.8 
304 Alloxazine 89.0 ± 4.9  944 Sertraline hydrochloride 101.1 ± 11.7 
305 DPO-1 89.1 ± 3.8  945 L-Canavanine 101.1 ± 4.7 
306 Orphenadrine hydrochloride 89.1 ± 18.3  946 Oxolinic acid 101.1 ± 12.4 
307 Sulfaphenazole 89.1 ± 34.9  947 S(+)-Isoproterenol (+)-bitartrate 101.2 ± 2.4 
308 Aminophylline ethylenediamine 89.2 ± 8.4  948 1-[2-
(Trifluoromethyl)phenyl]imidazol
e 
101.2 ± 9.4 
309 Cantharidin 89.3 ± 25.6  949 N^G,N^G-Dimethylarginine 
hydrochloride 
101.2 ± 10.7 
310 Cysteamine hydrochloride 89.3 ± 6.0  950 P1,P4-Di(adenosine-
5')tetraphosphate triammonium 
101.2 ± 10.2 
311 L-Glutamic acid, N-phthaloyl- 89.4 ± 32.8  951 Droperidol 101.2 ± 18.5 
312 CI-976 89.4 ± 17.7  952 Phosphoramidon disodium 101.2 ± 7.1 
313 2-Chloroadenosine triphosphate 
tetrasodium 
89.5 ± 23.0  953 Tetradecylthioacetic acid 101.3 ± 12.1 
314 (-)-Scopolamine methyl nitrate 89.5 ± 24.4  954 2,3-Butanedione 101.3 ± 15.0 
315 Procainamide hydrochloride 89.6 ± 33.7  955 U-99194A maleate 101.3 ± 8.9 
316 NBI 27914 89.7 ± 7.0  956 S-(-)-Carbidopa 101.3 ± 7.8 
317 Carbamazepine 89.8 ± 14.0  957 Oxotremorine methiodide 101.3 ± 18.6 
318 2-Chloro-2-deoxy-D-glucose 89.9 ± 5.0  958 Thio-NADP sodium 101.4 ± 10.4 
319 Furegrelate sodium 89.9 ± 4.6  959 Chlormezanone 101.4 ± 10.9 
320 AC-93253 iodide 89.8 ± 11.3  960 Acetohexamide 101.4 ± 13.1 
321 3-Aminopropylphosphonic acid 90.0 ± 2.1  961 4-Imidazolemethanol 
hydrochloride 
101.5 ± 8.2 
322 1,4-Dideoxy-1,4-imino-D-
arabinitol 
90.0 ± 6.2  962 (±)-Brompheniramine maleate 101.5 ± 4.3 
323 SKF 89626 90.1402627
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 963 L-2-aminoadipic acid 101.5 ± 9.7 
324 Tyrphostin AG 538 90.2 ± 14.0  964 (E)-4-amino-2-butenoic acid 101.5 ± 12.6 
325 Triprolidine hydrochloride 90.2 ± 0.5  965 Chlorzoxazone 101.5 ± 2.4 
326 Tyrphostin AG 1478 90.3 ± 8.9  966 Diazoxide 101.5 ± 12.2 
327 alpha-Lobeline hydrochloride 90.3 ± 6.6  967 Protriptyline hydrochloride 101.6 ± 7.3 
328 Centrophenoxine hydrochloride 90.4 ± 28.8  968 Mizoribine 101.6 ± 4.8 
329 Prochlorperazine dimaleate 90.4 ± 18.3  969 MDL 105,519 101.6 ± 19.9 
330 Varenicline tartrate 90.5 ± 2.6  970 Niclosamide 101.6 ± 22.5 
331 Metolazone 90.5 ± 39.1  971 5-Bromo-2'-deoxyuridine 101.6 ± 8.3 
332 B-HT 933 dihydrochloride 90.5 ± 9.0  972 (6R)-5,6,7,8-Tetrahydro-L-
biopterin hydrochloride 
101.6 ± 17.7 
333 Capsazepine 90.6 ± 11.8  973 Theobromine 101.7 ± 4.5 
334 Fenoldopam bromide 90.6 ± 5.5  974 (±)-PPHT hydrochloride 101.7 ± 5.1 
335 (±)-Synephrine 90.7 ± 28.9  975 Vanillic acid diethylamide 101.7 ± 2.4 
336 PD-161570 90.7 ± 9.1  976 Minocycline hydrochloride 101.7 ± 17.9 
337 1,10-Phenanthroline monohydrate 90.7 ± 13.0  977 Bepridil hydrochloride 101.8 ± 6.3 
338 Acepromazine maleate 90.7 ± 4.5  978 Diphenhydramine hydrochloride 101.8 ± 15.9 
339 (±)-2-Amino-5-
phosphonopentanoic acid 
90.8 ± 6.2  979 Tolbutamide 101.8 ± 7.4 
340 WAY-100635 maleate 90.8 ± 17.8  980 Dipropyldopamine hydrobromide 101.8 ± 8.0 
341 Atropine methyl nitrate 90.8 ± 8.8  981 Dobutamine hydrochloride 101.9 ± 15.9 
342 Benzamidine hydrochloride 90.8 ± 8.3  982 (±)-Nipecotic acid 101.9 ± 5.9 
343 Raloxifene hydrochloride 90.8 ± 14.0  983 Oxotremorine sesquifumarate salt 101.9 ± 13.3 
344 SC-236 90.8 ± 15.2  984 Iodoacetamide 101.9 ± 8.2 
345 Estrone 91.0 ± 8.5  985 ABT-418 hydrochloride 101.9 ± 4.7 
346 Kainic acid 90.1 ± 18.1  986 L-Hyoscyamine 101.9 ± 
12.00 
347 Pyrocatechol 91.0 ± 7.4  987 Clonidine hydrochloride 101.9 ± 9.8 
348 N-(4-Amino-2-
chlorophenyl)phthalimide 
91.1 ± 7.1  988 Terfenadine 101.9 ± 5.3 
349 Aminopterin 91.1 ± 3.5  989 Ouabain 102.0 ± 3.5 
350 5HPP-33 91.1 ± 9.2  990 Tocainide hydrochloride 102.0 ± 15.0 
351 NAN-190 hydrobromide 91.1 ± 29.0  991 S-Methyl-L-thiocitrulline acetate 102.0 ± 13.0 
352 L-732,138 91.1 ± 5.0  992 S-(+)-Fluoxetine hydrochloride 102.0 ± 9.9 
353 R(+)-Butylindazone 91.2 ± 11.8  993 N-p-Tosyl-L-phenylalanine 
chloromethyl ketone 
102.0 ± 13.7 
354 ML-9 91.2 ± 7.1  994 Histamine dihydrochloride 102.0 ± 10.2 
355 Molindone hydrochloride 91.2 ± 7.2  995 Daphnetin 102.0 ± 13.1 
356 NS8593 hydrochloride 91.2 ± 11.5  996 Dextromethorphan hydrobromide 
monohydrate 
102.0 ± 12.4 
357 Tetrabenazine 91.3 ± 18.4  997 Metaproterenol hemisulfate 102.0 ± 5.4 
358 Acetyl-beta-methylcholine 
chloride 
91.4 ± 19.2  998 Topotecan hydrochloride hydrate 102.0 ± 7.8 
359 (±)-Ibuprofen 91.4 ± 12.3  999 Isotharine mesylate 102.1 ± 6.6 
360 Tyrphostin AG 494 91.5 ± 7.4  1000 (±)-Sulpiride 102.1 ± 6.1 
361 Pheniramine maleate 91.5 ± 14.9  1001 U-101958 maleate 102.1 ± 9.0 
362 S-Ethylisothiourea hydrobromide 91.5 ± 10.5  1002 UK 14,304 102.1 ± 10.4 
363 2-(2-Aminoethyl)isothiourea 
dihydrobromide 
91.5 ± 12.4  1003 Flunarizine dihydrochloride 102.1 ± 8.8 
364 Amiodarone hydrochloride 91.5 ± 10.5  1004 CP-93129 dihydrochloride 
hydrate 
102.1 ± 6.9 
365 3-aminobenzamide 91.6 ± 2.5  1005 Ranitidine hydrochloride 102.1 ± 11.6 
366 Methylergonovine maleate 91.6 ± 8.0  1006 Levetiracetam 102.2 ± 9.6 
367 Azelaic acid 91.8 ± 5.2  1007 Phenylephrine hydrochloride 102.2 ± 12.7 
368 Molsidomine 91.8 ± 17.4  1008 Spermidine trihydrochloride 102.2 ± 19.0 
369 8-(4-Chlorophenylthio)-cAMP 
sodium 
91.8 ± 2.6  1009 Carmustine 102.2 ± 1.0 
370 1,3-Dimethyl-8-phenylxanthine 91.8 ± 4.8  1010 BW 723C86 102.2 ± 11.4 
371 3-Aminopropionitrile fumarate 91.9 ± 6.3  1011 Atropine methyl bromide 102.2 ± 7.3 
372 S-(4-Nitrobenzyl)-6-
thioguanosine 
91.9 ± 3.2  1012 9-cyclopentyladenine 102.2 ± 2.7 
373 Mianserin hydrochloride 92.0 ± 7.7  1013 5-Hydroxyindolacetic acid 102.3 ± 8.2 
374 Pyridostigmine bromide 92.0 ± 6.7  1014 CNS-1102 102.3 ± 11.4 
375 SB-366791 92.0 ± 7.1  1015 Enoximone 102.3 ± 5.2 
376 5-azacytidine 92.0 ± 10.7  1016 alpha,beta-Methylene adenosine 
5'-triphosphate dilithium 
102.3 ± 5.3 
377 Cortisone 21-acetate 92.1 ± 5.7  1017 Alfuzosin hydrochloride 102.3 ± 4.9 
378 ML-7 92.1 ± 9.6  1018 4-Methylpyrazole hydrochloride 102.3 ± 3.8 
379 Chlorpromazine hydrochloride 92.2 ± 10.3  1019 Cinnarizine 102.3 ± 5.4 
380 Adenosine 92.3 ± 7.9  1020 Ranolazine dihydrochloride 102.3 ± 13.7 
381 Pifithrin-mu 92.3 ± 34.4  1021 CP-101537 102.3 ± 6.7 
382 Methysergide maleate 92.3 ± 21.2  1022 8-Bromo-cGMP sodium 102.4 ± 7.4 
383 Rotenone 92.4 ± 12.1  1023 DL-alpha-Methyl-p-tyrosine 102.4 ± 5.8 
384 Stevioside 92.4 ± 13.9  1024 Lidocaine hydrochloride 102.4 ± 8.9 
385 Acetazolamide 92.4 ± 4.0  1025 Dihydroouabain 102.4 ± 11.9 
386 PD 168,077 maleate 92.4 ± 5.3  1026 Ciproxifan hydrochloride 102.4 ± 6.2 
387 Dihydrokainic acid 92.4 ± 30.0  1027 Thioridazine hydrochloride 102.5 ± 9.6 
388 BWB70C 92.4 ± 13.0  1028 Cytidine 5'-diphosphocholine 
sodium salt hydrate 
102.5 ± 15.7 
389 5-Fluoroindole-2-carboxylic acid 92.5 ± 8.9  1029 Acetylsalicylic acid 102.5 ± 9.1 
390 Zimelidine dihydrochloride 92.5 ± 9.4  1030 Amoxapine 102.6 ± 1.7 
391 Fiduxosin hydrochloride 92.6 ± 13.4  1031 Naltrexone hydrochloride 102.6 ± 6.5 
392 L-alpha-Methyl DOPA 92.6 ± 21.6  1032 1,1-Dimethyl-4-phenyl-
piperazinium iodide 
102.6 ± 13.3 
393 Salmeterol xinafoate 92.6 ± 8.3  1033 (S)-3,5-Dihydroxyphenylglycine 102.7 ± 20.4 
394 A-315456 92.6 ± 5.2  1034 Emetine dihydrochloride hydrate 102.7 ± 9.1 
395 Diphenyleneiodonium chloride 92.7 ± 5.6  1035 SQ 22536 102.7 ± 4.9 
396 Aminobenztropine 92.7 ± 5.2  1036 Terbutaline hemisulfate 102.8 ± 10.1 
397 2-Hydroxysaclofen 92.7 ± 0.2  1037 Tyrphostin AG 112 102.8 ± 4.7 
398 Budesonide 92.7 ± 8.6  1038 Trifluperidol hydrochloride 102.8 ± 9.3 
399 Glybenclamide 92.8 ± 16.7  1039 MHPG sulfate potassium 102.8 ± 6.8 
400 GR 113808 92.8 ± 8.0  1040 BRL 54443 maleate 102.8 ± 6.2 
401 6-Chloromelatonin 92.8 ± 24.3  1041 Pargyline hydrochloride 102.9 ± 12.8 
402 GR 55562 dihydrobromide 92.8 ± 13.3  1042 Bromoacetyl alprenolol menthane 102.8 ± 4.8 
403 Pilocarpine nitrate 92.9 ± 2.4  1043 Naratriptan hydrochloride 102.9 ± 17.6 
404 TTNPB 92.9 ± 11.5  1044 Fluoxetine hydrochloride 102.9 ± 7.1 
405 N6-Cyclohexyladenosine 92.9 ± 12.9  1045 1,3-Dipropyl-7-methylxanthine 102.9 ± 21.6 
406 Amperozide hydrochloride 92.9 ± 0.6  1046 Buspirone hydrochloride 102.9 ± 6.0 
407 Dopamine hydrochloride 93.0 ± 11.1  1047 Epibestatin hydrochloride 102.9 ± 13.0 
408 ODQ 93.0 ± 5.7  1048 cis-4-Aminocrotonic acid 103.0 ± 10.1 
409 Fusidic acid sodium 93.0 ± 9.1  1049 Indatraline hydrochloride 103.0 ± 8.6 
410 Maprotiline hydrochloride 93.0 ± 35.9  1050 (±)-Octopamine hydrochloride 103.0 ± 1.6 
411 Bezafibrate 93.0 ± 7.9  1051 SKF 86466 103.0 ± 12.5 
412 LY-310,762 hydrochloride 93.0 ± 7.5  1052 Iproniazid phosphate 103.0 ± 5.6 
413 beta-Lapachone 93.1 ± 5.0  1053 (-)-Sulpiride 103.0 ± 8.9 
414 (±)-Ibotenic acid 93.1 ± 9.6  1054 Carbachol 103.1 ± 3.5 
415 Tyrphostin A9 93.2 ± 14.5  1055 SR 2640 103.1 ± 17.1 
416 PK 11195 93.2 ± 6.1  1056 DL-alpha-
Difluoromethylornithine 
hydrochloride 
103.2 ± 12.1 
417 Cyclothiazide 93.2 ± 4.7  1057 ARL 67156 trisodium salt 103.2 ± 16.2 
418 L-703,606 oxalate salt hydrate 93.3 ± 4.4  1058 (±)-PD 128,907 hydrochloride 103.2 ± 2.1 
419 O-Phospho-L-serine 93.4 ± 14.4  1059 Ribavirin 103.3 ± 14.0 
420 Ofloxacin 93.4 ± 20.0  1060 S(-)-Timolol maleate 103.3 ± 4.5 
421 Quazinone 93.4 ± 5.4  1061 Phosphonoacetic acid 103.4 ± 12.3 
422 ICI 63,137 93.4 ± 5.4  1062 4-(2-Aminoethyl)benzenesulfonyl 
fluoride hydrochloride 
103.5 ± 4.8 
423 Suramin sodium salt 93.4 ± 9.0  1063 (±)-alpha-Methyl-4-
carboxyphenylglycine 
103.5 ± 10.0 
424 6-Methoxy-1,2,3,4-tetrahydro-
9H-pyrido[3,4b] indole 
93.4 ± 1.1  1064 Moxisylyte hydrochloride 103.5 ± 2.3 
425 (±)-Sotalol hydrochloride 93.5 ± 12.0  1065 YS-035 hydrochloride 103.5 ± 12.5 
426 YM 976 93.5 ± 3.0  1066 SR-95531 103.5 ± 3.4 
427 Meloxicam sodium 93.6 ± 6.8  1067 Methoctramine 
tetrahydrochloride 
103.6 ± 10.6 
428 SB 269970 hydrochloride 93.6 ± 22.9  1068 1-(m-Chlorophenyl)-biguanide 
hydrochloride 
103.6 ± 13.0 
429 4-Aminopyridine 93.6 ± 7.2  1069 (±)-Atenolol 103.6 ± 10.0 
430 Meclofenamic acid sodium 93.6 ± 9.6  1070 2',3'-dideoxycytidine 103.6 ± 6.0 
431 Lamotrigine 93.6 ± 9.2  1071 3-alpha,21-Dihydroxy-5-alpha-
pregnan-20-one 
103.6 ± 6.1 
432 Retinoic acid 93.6 ± 14.4  1072 Nylidrin hydrochloride 103.7 ± 6.3 
433 Beclomethasone 93.7 ± 1.6  1073 Dilazep hydrochloride 103.7 ± 12.7 
434 LP 12 hydrochloride hydrate 93.7 ± 9.5  1074 Quinolinic acid 103.7 ± 10.0 
435 TCPOBOP 93.7 ± 8.4  1075 Sulindac 103.7 ± 16.6 
436 Nimodipine 83.7 ± 4.5  1076 R(-)-Isoproterenol (+)-bitartrate 103.8 ± 21.4 
437 CB 1954 93.7 ± 2.8  1077 LP44 103.8 ± 8.7 
438 Aurintricarboxylic acid 93.7 ± 12.0  1078 PHA-543613 103.8 ± 13.6 
439 Ketorolac tris salt 93.7 ± 13.0  1079 Phenytoin sodium 103.8 ± 12.2 
440 Colchicine 93.8 ± 5.1  1080 1-(5-Isoquinolinylsulfonyl)-2-
methylpiperazine dihydrochloride 
103.8 ± 5.9 
441 3-deazaadenosine 93.8 ± 11.9  1081 Na-p-Tosyl-L-lysine 
chloromethyl ketone 
hydrochloride 
103.9 ± 14.0 
442 McN-A-343 93.8 ± 10.4  1082 Oxymetazoline hydrochloride 103.9 ± 10.0 
443 Ketotifen fumarate 93.8 ± 4.0  1083 (+)-Pilocarpine hydrochloride 103.9 ± 1.7 
444 BBMP 93.9 ± 9.9  1084 Tyrphostin 47 104.0 ± 4.7 
445 CP-66713 93.9 ± 10.2  1085 5-hydroxydecanoic acid sodium 104.0 ± 7.6 
446 Azathioprine 93.9 ± 5.0  1086 L-Canavanine sulfate 104.0 ± 8.6 
447 Guanidinyl-naltrindole di-
trifluoroacetate 
93.9 ± 7.0  1087 (+)-Cyclazocine 104.1 ± 10.3 
448 Fexofenadine hydrochloride 93.9 ± 3.6  1088 Cyclosporin A 104.1 ± 16.2 
449 1-Phenyl-3-(2-thiazolyl)-2-
thiourea 
94.0 ± 11.6  1089 2,4-Diamino-6-pyrimidinone 104.1 ± 13.8 
450 Dihydro-beta-erythroidine 
hydrobromide 
94.0 ± 5.4  1090 Alprenolol hydrochloride 104.1 ± 15.8 
451 Cimetidine 94.0 ± 4.0  1091 Nemadipine-A 104.1 ± 11.6 
452 Cortisone 94.0 ± 5.3  1092 (-)-MK-801 hydrogen maleate 104.1 ± 10.2 
453 JS-K 94.0 ± 5.4  1093 Tamoxifen citrate 104.2 ± 20.7 
454 CGP-74514A hydrochloride 94.1 ± 9.9  1094 U-69593 104.2 ± 10.1 
455 5-(N-Ethyl-N-
isopropyl)amiloride 
94.1 ± 7.3  1095 GR 127935 hydrochloride 
hydrate 
104.2 ± 8.3 
456 Metergoline 94.1 ± 8.5  1096 Trimipramine maleate 104.3 ± 7.1 
457 6-Hydroxymelatonin 94.1 ± 9.8  1097 L-alpha-Methyl-p-tyrosine 104.3 ± 4.3 
458 Chloroquine diphosphate 94.1 ± 9.1  1098 Pirenzepine dihydrochloride 104.3 ± 2.0 
459 (±)-p-Aminoglutethimide 94.1 ± 8.7  1099 GR-89696 fumarate 104.3 ± 9.0 
460 BMS-193885 94.2 ± 1.0  1100 2-methoxyestradiol 104.4 ± 10.2 
461 Cefotaxime sodium 94.2 ± 6.2  1101 Desipramine hydrochloride 104.4 ± 9.0 
462 Loperamide hydrochloride 94.2 ± 11.6  1102 Harmane 104.5 ± 8.0 
463 Org 24598 lithium salt 94.3 ± 5.8  1103 Carbetapentane citrate 104.5 ± 6.7 
464 N-(2-[4-(4-
Chlorophenyl)piperazin-1-
yl]ethyl)-3-methoxybenzamide 
94.3 ± 6.0  1104 Hemicholinium-3 104.5 ± 15.9 
465 Bumetanide 94.3 ± 2.5  1105 Caroverine hydrochloride 104.5 ± 21.3 
466 BTCP hydrochloride 94.3 ± 14.0  1106 Procaine hydrochloride 104.5 ± 8.1 
467 (+)-Catechin Hydrate 94.3 ± 10.9  1107 Phenylbutazone 104.5 ± 10.1 
468 Trovafloxacin mesylate 94.4 ± 17.2  1108 Bay 11-7082 104.6 ± 21.3 
469 Lumefantrine 94.4 ± 10.9  1109 Cephalothin sodium 104.6 ± 12.0 
470 GW9508 94.4 ± 0.8  1110 Amantadine hydrochloride 104.6 ± 3.5 
471 Clemastine fumarate 94.4 ± 2.5  1111 ICI 204,448 hydrochloride 104.6 ± 7.5 
472 NBQX disodium 94.5 ± 3.8  1112 Trazodone hydrochloride 104.7 ± 11.3 
473 Fluspirilene 94.5 ± 10.0  1113 2-Methyl-5-hydroxytryptamine 
maleate 
104.7 ± 14.7 
474 Spironolactone 94.5  ± 9.9  1114 17alpha-hydroxyprogesterone 104.8 ± 10.6 
475 SB 216763 94.5 ± 10.2  1115 (+)-MK-801 hydrogen maleate 104.8 ± 18.5 
476 2-Cyclooctyl-2-
hydroxyethylamine hydrochloride 
94.5 ± 6.6  1116 Famciclovir 104.8 ± 9.2 
477 Lonidamine 94.6 ± 7.2  1117 Hexahydro-sila-difenidol 
hydrochloride, p-fluoro analog 
104.8 ± 7.7 
478 (±) trans-U-50488 
methanesulfonate 
94.6 ± 5.3  1118 Alaproclate hydrochloride 104.8 ± 8.1 
479 Hypotaurine 94.6 ± 26.1  1119 SC 19220 105.0 ± 9.4 
480 LY-294,002 hydrochloride 94.6 ± 11.0  1120 DM 235 105.1 ± 10.7 
481 Amifostine 94.6 ± 2.0  1121 Pinacidil 105.1 ± 8.3 
482 Isoxanthopterin 94.7 ± 15.0  1122 2,2'-Bipyridyl 105.2 ± 7.5 
483 CNQX disodium 94.7 ± 15.8  1123 U-62066 105.2 ± 12.6 
484 Tetraethylammonium chloride 94.7 ± 8.6  1124 Naphazoline hydrochloride 105.3 ± 13.5 
485 Cambinol 94.8 ± 8.3  1125 4-Hydroxybenzhydrazide 105.3 ± 8.4 
486 SID7969543 94.8 ± 24.3  1126 Linopirdine 105.3 ± 3.6 
487 3,7-Dimethyl-1-
propargylxanthine 
94.8 ± 1.8  1127 PAC-1 105.3 ± 4.5 
488 SR 59230A oxalate 94.8 ± 26.7  1128 Cirazoline hydrochloride 105.5 ± 7.7 
489 Dantrolene sodium 94.8 ± 9.5  1129 Adenosine 3',5'-cyclic 
monophosphate 
105.5 ± 3.5 
490 DFB 94.8 ± 1.4  1130 L-745,870 hydrochloride 105.7 ± 4.1 
491 SNC80 94.8 ± 9.3  1131 Rhodblock 6 105.7 ± 10.7 
492 (±)-Muscarine chloride 94.8 ± 15.8  1132 Quinelorane dihydrochloride 105.7 ± 9.9 
493 Paliperidone 94.9 ± 1.6  1133 Cilostazol 105.8 ± 41.7 
494 NS-1619 94.9 ± 11.8  1134 Spermine tetrahydrochloride 105.8 ± 16.0 
495 (±)-p-Chlorophenylalanine 94.9 ± 9.4  1135 ML 10302 105.8 ± 6.4 
496 Tyrphostin 51 94.9 ± 2.9  1136 (-)-Eseroline fumarate 105.8 ± 9.3 
497 4-Hydroxy-3-
methoxyphenylacetic acid 
94.9 ± 9.6  1137 Levallorphan tartrate 105.9 ± 7.3 
498 Apomorphine hydrochloride 
hemihydrate 
95.0 ± 6.4  1138 5,5-Dimethyl-1-pyrroline-N-
oxide 
106.0 ± 5.3 
499 Betaine aldehyde chloride 95.0 ± 5.8  1139 Gemcitabine hydrochloride 106.0 ± 4.9 
500 D-Cycloserine 94.5 ± 6.4  1140 (±)-Propranolol hydrochloride 106.0 ± 10.5 
501 Ivermectin 94.5 ± 8.2  1141 Vincristine sulfate 106.1 ± 21.2 
502 TMB-8 hydrochloride 95.0 ± 0.4  1142 Nortriptyline hydrochloride 106.1 ± 17.3 
503 MHPG piperazine 95.1 ± 7.6  1143 Nalidixic acid sodium 106.1 ± 13.7 
504 Idarubicin 95.1 ± 1.7  1144 PPADS 106.1 ± 11.3 
505 Bromoacetylcholine bromide 95.1 ± 8.8  1145 Putrescine dihydrochloride 106.2 ± 11.7 
506 S-(4-Nitrobenzyl)-6-thioinosine 95.1 ± 33.3  1146 Haloperidol 106.2 ± 9.5 
507 SB 205384 95.1 ± 6.2  1147 Paromomycin sulfate 106.3 ± 7.8 
508 TMPH hydrochloride 95.1 ± 13.7  1148 Pentolinium di[L(+)-tartrate] 106.3 ± 2.7 
509 Tetraisopropyl 
pyrophosphoramide 
952 ± 1.5  1149 Xylazine hydrochloride 106.3 ± 5.8 
510 N-Phenylanthranilic acid 95.2 ± 6.4  1150 CGP 20712A methanesulfonate 106.4 ± 13.7 
511 Nimustine hydrochloride 95.2 ± 13.6  1151 (+)-Quisqualic acid 106.4 ± 10.3 
512 Cibenzoline succinate 95.2 ± 7.2  1152 Decamethonium dibromide 106.4 ± 21.3 
513 Aconitine 95.2 ± 4.4  1153 H-8 dihydrochloride 106.4 ± 6.7 
514 BP 897 95.2 ± 9.6  1154 Metoclopramide hydrochloride 106.5 ± 2.9 
515 Efaroxan hydrochloride 95.2 ± 6.3  1155 (-)-Cotinine 106.5 ± 4.3 
516 Bay 11-7085 95.2 ± 7.7  1156 L-Mimosine from Koa hoale 
seeds 
106.5 ± 13.7 
517 SC-51089 hydrate 95.2 ± 13.2  1157 Melatonin 106.6 ± 11.6 
518 Benzamil hydrochloride 95.3 ± 5.6  1158 S(-)-UH-301 hydrochloride 106.6 ± 12.1 
519 (±)-Isoproterenol hydrochloride 95.3 ± 10.4  1159 Ipratropium bromide 106.7 ± 26.2 
520 (±)-Bay K 8644 95.3 ± 3.4  1160 Xylometazoline hydrochloride 106.7 ± 10.4 
521 SKF-525A hydrochloride 95.3 ± 9.0  1161 Taurine 106.8 ± 10.4 
522 Triamterene 95.3 ± 10.4  1162 Prilocaine hydrochloride 106.9 ± 9.7 
523 1-(5-Isoquinolinylsulfonyl)-3-
methylpiperazine dihydrochloride 
95.4 ± 14.7  1163 Naltriben methanesulfonate 106.9 ± 8.0 
524 4-Amino-1,8-naphthalimide 95.4 ± 12.1  1164 MG 624 106.9 ± 11.5 
525 Pentylenetetrazole 95.4 ± 8.7  1165 Ancitabine hydrochloride 106.9 ± 5.2 
526 5-fluoro-5'-deoxyuridine 95.4 ± 4.3  1166 Bisoprolol hemifumarate salt 106.9 ± 6.1 
527 Ifenprodil tartrate 95.4 ± 10.6  1167 Telenzepine dihydrochloride 107.0 ± 15.2 
528 Ruthenium red 95.4 ± 2.3  1168 Proglumide 107.1 ± 0.6 
529 R(+)-IAA-94 95.5 ± 13.0  1169 L-Methionine sulfoximine 107.1 ± 5.4 
530 (±)-Normetanephrine 
hydrochloride 
95.5 ± 24.8  1170 Mevastatin 107.1 ± 10.0 
531 D-609 potassium 95.5 ± 4.1  1171 Ro 8-4304 107.2 ± 11.5 
532 A3 hydrochloride 95.5 ± 8.6  1172 Phaclofen 107.2 ± 18.9 
533 5-(N,N-Dimethyl)amiloride 
hydrochloride 
95.5 ± 2.7  1173 Tizanidine hydrochloride 107.2 ± 6.1 
534 Propantheline bromide 95.5 ± 4.8  1174 O-Methylserotonin hydrochloride 107.2 ± 4.7 
535 Ibandronate sodium 95.5 ± 10.4  1175 Stattic 107.3 ± 19.6 
536 CX 546 95.5 ± 26.6  1176 Doxylamine succinate 107.4 ± 0.7 
537 Tetramisole hydrochloride 95.5 ± 22.8  1177 Ropinirole hydrochloride 107.5 ± 15.4 
538 GABA 95.6 ± 8.2  1178 Muscimol hydrobromide 107.5 ± 2.4 
539 Cephradine 95.6 ± 1.1  1179 Mibefradil dihydrochloride 107.6 ± 26.6 
540 Enalaprilat dihydrate 95.6 ± 2.1  1180 Hydroxyurea 107.6 ± 23.3 
541 3-Tropanylindole-3-carboxylate 
methiodide 
95.6 ± 4.9  1181 S(+)-Ibuprofen 107.7 ± 17.0 
542 Cyproterone acetate 95.6 ± 2.1  1182 (2S,1'S,2'S)-2-
(carboxycyclopropyl)glycine 
107.7 ± 15.6 
543 PAPP 95.6 ± 9.9  1183 Chlorothiazide 107.7 ± 8.4 
544 A-68930 hydrochloride 95.6 ± 9.3  1184 VER-3323 hemifumarate salt 107.7 ± 7.9 
545 Hydrochlorothiazide 95.6 ± 3.9  1185 6-Nitroso-1,2-benzopyrone 107.9 ± 12.7 
546 DL-p-Chlorophenylalanine 
methyl ester hydrochloride 
95.7 ± 6.7  1186 PD-166285 hydrate 108.1 ± 4.5 
547 GBR-12909 dihydrochloride 95.7 ± 6.3  1187 Ethopropazine hydrochloride 108.3 ± 15.2 
548 Acetylthiocholine chloride 95.7 ± 4.8  1188 1-Amino-1-
cyclohexanecarboxylic acid 
hydrochloride 
108.3 ± 1.1 
549 Furosemide 95.7 ± 5.9  1189 S(-)-3PPP hydrochloride 108.4 ± 3.1 
550 Tranilast 95.7 ± 1.4  1190 MRS 2179 108.4 ± 2.3 
551 (±)-Epinephrine hydrochloride 95.7 ± 7.0  1191 Norcantharidin 108.5 ± 19.2 
552 IMS2186 95.7 ± 10.2  1192 L-687,384 hydrochloride 108.6 ± 4.6 
553 Benoxathian hydrochloride 95.8 ± 4.4  1193 Hydroxytacrine maleate 108.6 ± 13.0 
554 3,4-Dichloroisocoumarin 95.8 ± 9.3  1194 N2-Ethyl-2'-deoxyguanosine 108.7 ± 6.3 
555 Caffeine 95.8 ± 4.7  1195 (±)-Thalidomide 108.7 ± 11.6 
556 Serotonin hydrochloride 95.8 ± 9.3  1196 Ro 20-1724 108.8 ± 2.1 
557 6-Methyl-2-
(phenylethynyl)pyridine 
hydrochloride 
95.8 ± 6.2  1197 (-)-trans-(1S,2S)-U-50488 
hydrochloride 
108.9 ± 5.7 
558 (+)-Hydrastine 95.9 ± 10.1  1198 alpha-Methyl-DL-tyrosine methyl 
ester hydrochloride 
108.9 ± 8.2 
559 L-Beta-threo-benzyl-aspartate 95.9 ± 9.2  1199 6-Aminohexanoic acid 109.0 ± 9.6 
560 Aniracetam 95.9 ± 3.1  1200 Picotamide 109.0 ± 15.4 
561 SKF 89976A hydrochloride 95.9 ± 25.1  1201 NG-Nitro-L-arginine methyl ester 
hydrochloride 
109.0 ± 16.7 
562 N,N,N',N'-
Tetramethylazodicarboxamide 
95.9 ± 2.2  1202 CR 2249 109.1 ± 19.6 
563 Ro 25-6981 hydrochloride 95.9 ± 5.0  1203 Tolazamide 109.2 ± 9.0 
564 Steviol 95.9 ± 19.9  1204 Prazosin hydrochloride 109.3 ± 23.7 
565 Triamcinolone 95.9 ± 21.3  1205 Zaprinast 109.4 ± 6.4 
566 5,5-Diphenylhydantoin 95.9 ± 12.2  1206 D(-)-2-Amino-5-
phosphonopentanoic acid 
109.4 ± 11.9 
567 Arecaidine propargyl ester 
hydrobromide 
96.0 ± 12.2  1207 N-Methyl-D-aspartic acid 109.5 ± 4.3 
568 Benztropine mesylate 96.0 ± 5.8  1208 3-Tropanyl-indole-3-carboxylate 
hydrochloride 
109.6 ± 9.2 
569 Clorgyline hydrochloride 96.0 ± 4.2  1209 NNC 55-0396 109.8 ± 31.5 
570 MDL 28170 96.0 ± 2.8  1210 2,6-Difluoro-4-[2-
(phenylsulfonylamino)ethylthio]p
henoxyacetamide 
109.8 ± 13.1 
571 Cyproheptadine hydrochloride 96.0 ± 5.5  1211 BNTX maleate salt hydrate 109.9 ± 5.7 
572 Riluzole 96.0 ± 3.6  1212 Memantine hydrochloride 109.9 ± 10.5 
573 (±)-2-Amino-3-
phosphonopropionic acid 
96.0 ± 3.9  1213 2,3-Butanedione monoxime 109.9 ± 13.3 
574 Propofol 96.0 ± 3.0  1214 Piracetam 110.0 ± 4.3 
575 8-Cyclopentyl-1,3-
dimethylxanthine 
96.1 ± 9.6  1215 Doxepin hydrochloride 110.0 ± 13.2 
576 Acetamide 96.1 ± 7.6  1216 Chelidamic acid 110.2 ± 8.8 
577 Arcaine sulfate 96.1 ± 6.4  1217 BIA 2-093 110.6 ± 5.0 
578 Nitrendipine 96.1 ± 17.4  1218 Cortexolone 110.6 ± 19.2 
579 R(-)-Propylnorapomorphine 96.1 ± 7.1  1219 T0070907 110.9 ± 6.0 
hydrochloride 
580 Voriconazole 96.1 ± 10.4  1220 R-(+)-7-Hydroxy-DPAT 
hydrobromide 
110.9 ± 7.0 
581 Primidone 96.1 ± 4.9  1221 Naltrindole hydrochloride 111.0 ± 9.1 
582 CP-135807 96.1 ± 6.8  1222 (±)-Taxifolin 111.1 ± 7.5 
583 N-Methyldopamine 
hydrochloride 
96.1 ± 15.9  1223 Propafenone hydrochloride 111.3 ± 10.1 
584 (±)-AMPA hydrobromide 96.2 ± 10.6  1224 3-Nitropropionic acid 111.3 ± 13.2 
585 JL-18 96.2 ± 7.5  1225 Methapyrilene hydrochloride 111.4 ± 10.2 
586 Lidocaine N-ethyl bromide 
quaternary salt 
96.2 ± 12.5  1226 Sobuzoxane 111.5 ± 7.6 
587 Phenylbenzene-omega-
phosphono-alpha-amino acid 
96.2 ± 4.8  1227 Quinidine sulfate 111.6 ± 16.6 
588 1-Phenylbiguanide 96.2 ± 2.3  1228 N-omega-Methyl-5-
hydroxytryptamine oxalate salt 
111.6 ± 33.8 
589 R(+)-SCH-23390 hydrochloride 96.2 ± 12.3  1229 CP-31398 dihydrochloride 
hydrate 
111.8 ± 1.4 
590 Ganciclovir 96.3 ± 6.5  1230 NADPH tetrasodium 112.0 ± 13.1 
591 NSC 95397 96.3 ± 15.0  1231 S-Methylisothiourea hemisulfate 112.2 ± 21.2 
592 Glipizide 96.3 ± 1.2  1232 Methiothepin mesylate 112.2 ± 9.4 
593 Cefazolin sodium 96.3 ± 4.6  1233 NG-Monomethyl-L-arginine 
acetate 
112.2 ± 7.1 
594 Nicardipine hydrochloride 96.3 ± 24.2  1234 BRL 52537 hydrochloride 112.4 ± 4.2 
595 Droxinostat 96.3 ± 1.9  1235 Spiroxatrine 112.7 ± 3.0 
596 Genipin 96.3 ± 9.0  1236 Idazoxan hydrochloride 112.7 ± 7.0 
597 L-N6-(1-Iminoethyl)lysine 
hydrochloride 
96.4 ± 1.7  1237 Metolazone 112.9 ± 23.7 
598 Sorbinil 96.4 ± 14.0  1238 (±)-Vesamicol hydrochloride 112.9 ± 7.4 
599 Pirfenidone 96.4 ± 15.8  1239 (-)-Tetramisole hydrochloride 112.9 ± 6.8 
600 Sodium Oxamate 96.5 ± 14.4  1240 L-Glutamic acid hydrochloride 113.0 ± 19.3 
601 NO-711 hydrochloride 95.5 ± 5.2  1241 Niflumic acid 113.3 ± 19.3 
602 Rauwolscine hydrochloride 96.5 ± 8.7  1242 3-Morpholinosydnonimine 
hydrochloride 
114.0 ± 15.4 
603 cis-(Z)-Flupenthixol 
dihydrochloride 
96.5 ± 4.1  1243 (±)-Verapamil hydrochloride 114.0 ± 7.1 
604 3-Amino-1-propanesulfonic acid 
sodium 
96.5 ± 4.6  1244 Nimesulide 114.0 ± 22.1 
605 SC-58125 96.5 ± 13.6  1245 (±)-CGP-12177A hydrochloride 114.1 ± 10.3 
606 Sivelestat sodium salt hydrate 96.6 ± 6.4  1246 Naloxone hydrochloride 114.3 ± 14.2 
607 Epinastine hydrochloride 96.6 ± 14.2  1247 GW9662 114.5 ± 11.5 
608 Cystamine dihydrochloride 96.6 ± 12.8  1248 Noscapine hydrchloride 114.6 ± 20.4 
609 Chlorprothixene hydrochloride 96.6 ± 7.7  1249 1-(2-Methoxyphenyl)piperazine 
hydrochloride 
114.8 ± 8.3 
610 (±)-HA-966 96.6 ± 6.4  1250 alpha-Methyl-5-
hydroxytryptamine maleate 
115.5 ± 12.2 
611 ATPA 96.6 ± 6.2  1251 ZM 39923 hydrochloride 115.5 ± 23.0 
612 SD-169 96.7 ± 5.5  1252 1-Methylimidazole 115.7 ± 16.4 
613 Minoxidil 96.7 ± 6.2  1253 (-)-Perillic acid 115.8 ± 16.6 
614 Promethazine hydrochloride 96.7 ± 11.4  1254 Quinine sulfate 116.2 ± 16.5 
615 Imipenem monohydrate 96.8 ± 2.2  1255 p-MPPF dihydrochloride 117.8 ± 19.4 
616 Piperaquine tetraphosphate 
tetrahydrate 
96.8 ± 7.2  1256 SKF 95282 dimaleate 120.1 ± 40.0 
617 3-Iodo-L-tyrosine 96.8 ± 8.8  1257 5-Nitro-2-(3-
phenylpropylamino)benzoic acid 
120.8 ± 13.5 
618 Aprindine hydrochloride 96.8 ± 13.3  1258 NG-Nitro-L-arginine 120.0 ± 6.8 
619 S-(-)-Eticlopride hydrochloride 96.8 ± 1.1  1259 MDL 26,630 trihydrochloride 124.5 ± 16.5 
620 (+)-Chlorpheniramine maleate 96.8 ± 6.2  1260 7-Nitroindazole 126.0 ± 15.1 
621 Astaxanthin 96.8 ± 4.6  1261 S-Nitroso-N-acetylpenicillamine 
 
127.5 ± 10.1 
622 Ara-G hydrate 96.8 ± 6.9  1262 Methoxamine hydrochloride 132.3 ± 57.0 
623 Picrotoxin 96.8 ± 4.1  1263 JFD00244 113.9 ± 48.7 
 
624 Nialamide 96.8 ± 7.4  1264 (±)-Butaclamol hydrochloride ND 
625 Lomefloxacin hydrochloride 96.9 ± 10.1  1265 (±)-Quinpirole dihydrochloride ND 
626 Eletriptan hydrobromide 96.9 ± 5.3  1266 Aurothioglucose ND 
627 nor-Binaltorphimine 
dihydrochloride 
96.9 ± 14.7  1267 
Bethanechol chloride 
ND 
628 Bicalutamide (CDX) 96.9 ± 5.3  1268 DL-Buthionine-[S,R]-
sulfoximine 
ND 
629 Cinoxacin 96.9 ± 2.7  1269 GBR-12935 dihydrochloride ND 
630 (±)-gamma-Vinyl GABA 96.9 ± 7.5  1270 Guanfacine hydrochloride ND 
631 3-Tropanyl-3,5-dichlorobenzoate 96.9 ± 4.1  1271 GW5074 ND 
632 DL-threo-beta-hydroxyaspartic 
acid 
97.0 ± 9.5  1272 
L-162,313 
ND 
633 3,4-Dihydroxyphenylacetic acid 97.0 ± 9.9  1273 m-Iodobenzylguanidine 
hemisulfate 
ND 
634 Olomoucine 97.0 ± 10.1  1274 MK-912 ND 
635 Milrinone 97.0 ± 4.9  1275 PD-407824 ND 
636 Antozoline hydrochloride 97.0 ± 6.0  1276 Progesterone ND 
637 S15535 97.0 ± 1.3  1277 Propentofylline ND 
638 Urapidil hydrochloride 97.1 ± 1.5  1278 Protoporphyrin IX disodium ND 
639 Trifluoperazine dihydrochloride 97.1 ± 25.1     
640 L-Arginine 97.1 ± 5.5     
  
	
	
